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1.  Natural history and clinical description of IgA
 Nephropathy
IgA nephropathy (IgAN), fi rst described by Berger and Hinglais in 1968, is 
the most common primary glomerulonephritis worldwide [1-3]. The disease 
is characterized by mesangial deposits of IgA, predominantly polymeric IgA 
(pIgA) of the IgA1 subclass, and found on immunofl uorescence staining 
of kidney sections. Co-deposition of complement factor C3 together with 
properdin is often present [4;5]. Next to IgA, IgG is also present in a 
substantial percentage of the biopsies, while IgM is only rarely found. On light 
microscopy the picture can vary from slight mesangial hypertrophy to extra 
capillary proliferation of glomeruli, with sclerosis and interstitial fi brosis. 
 IgAN occurs at any age, but most commonly the age of onset is in the 
second or third decade of life. Males are more often affected than females. The 
overall male:female ratio is 2:1. No exact data on incidence rates are available, 
but incidence rates seem to be higher in certain countries like Japan, Australia 
and Southern Europe. In the United Kingdom, Canada and the United States 
of America incidence rates seem to be lower [6]. Whether these differences 
are determined by geographical or genetic factors is not clear. Besides it is 
important to realise that data on incidence rates depend on referral rates and 
on biopsy policy, which might be different in certain countries. 
 Most patients with IgAN present with microscopic hematuria with or 
without mild proteinuria. About 40% of patients have episodes of macroscopic 
hematuria. This is sometimes preceded by infections, most commonly upper 
respiratory tract infections. This phenomenon is called synpharyngitic 
hematuria [7;8]. Other infections like gastro-intestinal or urinary tract infections 
have also been reported to precede macroscopic hematuria [9;10]. Proteinuria 
is common and can vary from mild proteinuria to nephrotic syndrome. There 
is still no specifi c treatment that infl uences mesangial IgA deposition. Patients 
with proteinuria of >1 gram per 24 hour and those with hypertension should 
be treated with angiotensin-converting enzyme inhibitors and angiotensin 
receptor blockers. The use of prednisone and other immunosuppressive agents 
should be limited to those patients who present with acute renal failure and 
crescentic glomerulonephritis [11].
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IgAN has been considered a benign disease for a long time, but nowadays 
it is clear that eventually 30-40% of patients will develop renal failure. In 
Western Europe and the United States of America 7-10% of the patients on 
renal replacement therapy suffer from IgAN [12]. The severity of histological 
lesions is correlated with renal function, especially severe sclerosis and 
tubulointerstitial damage correlate with poor outcome [13]. Next to histological 
lesions, unfavourable outcome is associated with persistent hematuria and 
proteinuria of more than 1 gram per 24 hours, decreased glomerular fi ltration 
rate (GFR) at the time of the diagnosis, and hypertension. Although several 
laboratory tests have been suggested to correlate with clinical outcome, so far 
no reliable biomarker has been identifi ed to predict outcome in IgAN [14-16]. 
Recurrence of IgAN after renal transplantation is very common, suggesting 
that IgAN is a systemic disease [17]. Another argument that IgAN is a 
systemic disease comes from the observation that IgA depositions disappear 
from a kidney of an IgAN patient, after transplantation of this kidney to a non 
IgAN patient [18].
2.  Characteristics of IgA
2.1  Human IgA immune system
The human IgA system is complex, as human IgA is produced at many 
different sites in the body and exists in different forms. The majority of IgA is 
produced by mucosal tissue and secreted as secretory IgA (SIgA). A smaller 
amount of IgA is produced by plasma cells in the bone marrow and appears in 
the circulation. These different compartments, the mucosal and the systemic, 
are linked by the so called mucosa-bone marrow axis and do not function 
independent from each other [19]. 
 There are two subclasses of human IgA, IgA1 and IgA2. The main 
structural difference between the subclasses is the 18-amino acid hinge region, 
which is lacking in IgA2 [20]. IgA2 has two different allotypes IgA2m1 
and IgA2m2 [20]. Both IgA1 and IgA2 exist in monomeric (mIgA) and in 
polymeric forms (pIgA). PIgA consists of dimeric IgA (dIgA), but also larger 
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molecules exist. Dimeric IgA consist of two IgA molecules linked with a 21 
kD joining protein, the J chain. IgA and J chain are co synthesized by plasma 
cells and polymers are assembled before secretion [21;22]. The composition 
of pIgA is variable and may consists of complexes of IgA and the FcαRI/
CD89, IgA immune complexes and IgA-fi bronectin complexes [23;24]. As 
mentioned before, IgA at mucosal tissues consists mainly of SIgA, which 
consist of dimeric IgA with secretory component, derived from the mucosal 
epithelium (Figure 1). 
Monomeric IgA
Dimeric IgA
J-chain
A
B
V
V
C C C
Fab Hinge
region
Fc
J-chain
Secretory componentC
Secretory IgA
C
Figure 1. Different forms of human IgA. Human IgA consists of molecules with different 
sizes and structures. Monomeric IgA (mIgA) is a single IgA molecule with 2 heavy chains 
(grey), both containing 1 variable (V) and 3 constant (C) domains, and 2 light chains (black), 
each containing 1 variable and 1 constant domain. This results in a constant part of the molecule 
(Fc) and an antibody binding part (Fab), connected to each other by the hinge region of the 
molecule (A). Dimeric IgA (dIgA) consists of two single IgA molecules, joined by J-chain (B). 
Secretory IgA (SIgA) consists of dimeric IgA connected to secretory component (C).
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Although IgA is mainly produced at the mucosa, IgA is also present in the 
systemic compartment in a concentration of 2-3 mg/ml. Serum IgA exists 
mainly as IgA1 (90%) and is predominantly monomeric IgA. Like other 
immunoglobulins in serum, IgA is produced by plasma cells in the bone 
marrow. The function of systemic IgA is not well understood. It might be that 
IgA is involved in the regulation of immune responses in an anti-infl ammatory 
way [25]. On the other hand the complex of the IgA receptor CD89 with IgA 
has probably pro-infl ammatory effects. These complexes have been shown 
to be present in IgAN patients and in an animal model their presence was 
associated with IgA deposition and glomerulonephritis [26;27].
 The function of the mucosal compartment is better understood and will 
be discussed more extensively in the following paragraph.
2.2  Mucosal IgA compartment
IgA is the major immunoglobulin in mucosal secretions and has an important 
function in mucosal defence against bacterial and viral infections. IgA at 
mucosal surfaces is mainly dimeric and secreted as secretory IgA (SIgA). 
Before secretion dIgA is bound to the polymeric Ig receptor (pIgR), located at 
the basolateral site of the mucosal epithelium. Then IgA is transported to the 
mucosal surface, where it is secreted together with a proteolytically cleaved 
part of the pIgR (secretory component). 
 Both subclasses IgA1 and IgA2 are produced at the mucosa. The 
distribution of the two subclasses varies at different mucosal sites. In the 
nasal mucosa the relative contribution of IgA1 is 93% and in the bronchial 
mucosa 75%. In the proximal gastrointestinal tract the relative contribution 
of IgA1 is high, 83% at the gastric mucosa, and low in the distal part, 36% 
in the colon [28]. Although the major part of SIgA is present in secretions 
of the gastrointestinal tract and the respiratory tract, small amounts of SIgA 
are also found in the circulation [29;30]. The potential role of SIgA in the 
pathogenesis in IgAN will be discussed in more detail in chapter 5. 
 There is a cross talk between mucosal sites in the human body. This 
means that an immune response induced at one mucosal site will result in an 
immune response with the same antigen specifi city at another mucosa and 
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even might induce a clear systemic immune response. The different mucosae 
can be seen as a common mucosal immune system [31]. On the other hand 
in many cases a mucosal immune response will not give rise to a systemic 
immune response, this phenomenon is called mucosal tolerance [32].
3. Mesangial IgA in IgA Nephropathy
3.1 Mechanisms of IgA deposition
The hallmark of IgAN is the presence of mesangial IgA depositions. The 
mechanism or mechanisms by which IgA accumulates are so far incompletely 
understood. Deposition of IgA in IgAN cannot simply be explained by high 
serum levels of IgA, as other diseases with high levels of serum IgA do not 
show deposition of IgA in the mesangium. 
 The binding of IgA to the mesangium can either be specifi c, directed 
against certain antigens or by specifi c receptors, or the binding can be non-
specifi c. So far no auto-antibodies directed against specifi c mesangial antigens 
have been described in IgAN [33]. Therefore IgAN is not considered an auto-
immune disease. 
 In vitro studies showed binding of IgA to human mesangial cells 
(HMC) [34-36]. It has been suggested that specifi c IgA receptors, like the 
FcαRI receptor, CD89, are present on HMC and responsible for the binding of 
IgA to these cells. However, so far no CD89 has been detected on HMC [37]. 
Also other receptors like the asialoglycoprotein receptor or the transferrin 
receptor have been suggested to be involved in the binding of IgA in IgAN 
[38;39]. Although these receptors are present on HMC, no abnormalities in 
the expression or the function of one of these receptors has been shown in 
IgAN patients. 
 The size distribution of circulating IgA and IgA-containing immune 
complexes (IgA-IC) seems to be involved in the mechanism of IgA deposition. 
In animal models aggregates of mainly polymeric IgA induced glomerular 
infl ammation, whereas monomeric IgA did not induce infl ammation [40]. 
In IgAN patients levels of IgA-IC are elevated [24;41]. It is likely that the 
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higher serum levels of IgA-IC will promote mesangial deposition through 
size dependent trapping [42].
 The possible role of altered glycosylation of IgA1 as a factor involved 
in the mechanism of deposition will be discussed in paragraph 4. 
3.2  Consequences of mesangial IgA depositions
Once IgA is present in the mesangium it may have an effect on the renal 
tissue via various routes. IgA can activate the complement system via the 
alternative pathway and via the mannose binding lectin (MBL) route [43;44]. 
MBL activation by IgA is restricted to polymeric IgA, which is the main type 
of mesangial IgA [44]. Recently it has been shown in renal biopsies that IgA 
deposits co-localize with MBL and that activation of the complement system 
via the MBL route is associated with more severe glomerular injury [45]. 
Activation of the complement system via either route will eventually result 
in formation of the terminal complex C5b-9, which can activate mesangial 
cells to produce inflammatory mediators and growth factors. Of the different 
growth factors, transforming growth factor-β (TGF-β) and platelet derived 
growth factor (PDGF) have been suggested to be involved in progressive 
inflammation in IgAN [23].
4.  IgA in IgA Nephropathy
Levels of plasma IgA1 are elevated in about half of the IgAN patients [46;47]. 
The elevated IgA concentration seems to be the result of higher production of 
IgA by plasma cells in the bone marrow [48-51]. The fact that other diseases 
with high serum IgA concentrations, like multiple myeloma or HIV, are 
not associated with renal IgA depositions supports the idea that the higher 
IgA1 concentrations are not the only cause of mesangial IgA deposition in 
IgAN. Next to the higher concentrations of IgA1 qualitative changes of IgA 
in IgAN patients have been described. The most important change in IgA is 
the glycosylation pattern of IgA1 in IgAN patients. IgA of IgAN patients 
contains a reduced galactosylation of the O-linked glycans in the hinge 
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region [52-56]. The hinge region consists of 17 amino-acids, of which 6 are 
0-linked glycosylation sites. The same abnormality in glycosylation pattern 
is found in IgA produced in vitro by tonsillar lymphocytes, suggesting that 
tonsils might contribute to the abnormally glycosylated IgA in serum [57;58]. 
IgA glycosylation takes place in the golgi apparatus. Recently specifi c 
glycosyltransferases have been described, but so far no abnormalities in 
expression or in function were demonstrated in IgAN [3]. A more extensive 
discussion on the role of glycosylation is given in chapter 7. In the urine 
of IgAN patients immune complexes containing aberrantly glycosylated IgA 
have been described. These complexes were not present in patients with other 
glomerular diseases [59]. Recently it has been suggested that a lectin-binding 
assay, based on the detection of undergalactosylated IgA1, might have 
potential as a non-invasive diagnostic test for IgA nephropathy [60]. 
 Our hypothesis is that the quantitative and qualitative abnormalities of 
IgA in IgAN patients are the result of a disturbed regulation of the immune 
response. Therefore we focussed on different processes of the immune 
response, in particular of the primary immune response of IgAN patients in 
comparison with controls.
5.  Production of IgA
5.1  Regulation of IgA production
Production of IgA antibodies is a tightly regulated process, and is controlled 
at several levels. Naïve B cells express surface IgM/IgD and have to go 
through a process of clonal expansion, isotype switching, affi nity maturation 
and differentiation before IgA plasma cells have developed. The process 
of class switch recombination (CSR) occurs by looping out and deletion of 
segments of the DNA [61;62]. Induction of Ig secretion can be mediated by 
both T cell-dependent and T cell-independent antigens, operating via different 
mechanisms. The T cell dependent mechanism is mainly dependent on the 
CD40-CD40-ligand interaction. In the hyper IgM syndrome a genetic alteration 
of CD40L results in the absence of IgA and IgG [63;64]. For IgA production 
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cytokines like transforming growth factor β (TGF-β), IL-2 and IL-10 have 
been shown to be involved [65]. The T cell-independent route of Ig class 
switching can be induced by Dendritic cells (DC), via expression of surface 
molecules like B lymphocyte stimulator protein (BlyS, also called BAFF or 
TALL-1) and a proliferation-inducing ligand (APRIL), both members of the 
TNF-TNF-R family, like CD40-CD40L [66].
5.2  General characteristics of dendritic cells in immune regulation
Dendritic cells (DC) are professional antigen presenting cells that play a 
critical role in the initiation and regulation of immune responses [67;68]. An 
important characteristic of DC is their potency to migrate from blood to tissues 
and to lymph nodes. DC are abundantly present in the skin and in mucosal 
tissue of the gastrointestinal tract and the respiratory tract [69]. Besides, 
DC are present in most peripheral organs, including the kidney [70;71]. In 
most tissues DC are present in an immature state. Immature DC have a high 
capacity to capture antigens [67]. After capturing antigens, DC can migrate to 
lymphoid tissue, like lymph nodes. As a consequence of antigen uptake DC 
will maturate and differentiate in distinctive ways, dependent on the type of 
stimulus that is given to the DC. After maturation DC express co-stimulatory 
molecules and adhesion molecules on their cell surface and are able to present 
antigens to T cells in the context of major histocompatibilty (MHC) molecules. 
This process then leads to T cell activation, proliferation and infi ltration to the 
site of infl ammation. DC are actively involved in the immunological response 
and additionally play a crucial role in maintenance of self tolerance. In the 
thymus DC can present self-antigens in the context of MHC and T cells with a 
too high affi nity are deleted (negative selection) [72]. So DC are involved and 
decisive in different immunological processes. On the one hand DC induce 
immune responses directed against bacteria’s and viruses, on the other hand 
DCs are involved in prevention of auto-immunity.
 In humans different subsets of DC can be distinguished, based on 
different phenotypic characteristics: 1) Langerhans cells and interstitial DC, 
both belonging to the myeloid lineage and 2) plasmacytoid DC, which are 
thought to be derived from a lymphoid precursor. Langerhans cells, which
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Figure 2. Basic principles of the regulation of IgA production. A naïve B cell has to un-
dergo a process of activation, proliferation, somatic hypermutation and affi nity maturation, 
class switch recombination and differentiation, before is has become an IgA producing plasma 
cell. This process can occur either T cell dependent or T cell independent. 
In the traditional model of T cell dependent activation, an antigen presenting cell (APC), 
takes up antigen (Ag), processes this and presents peptides in the context of MHC II to CD4+ 
T cells. This mechanism is dependent on co-stimulatory molecules like CD80/86 and CD28. 
Activated T cells secrete a variety of immunostimulatory factors including cytokines and start 
to express CD40L. The subsequent interaction of activated T cells and B cells through CD40-
CD40L and the cytokine milieu, possibly also derived from the mucosal environment, will 
together determine the production of IgA. In this model, Ag specifi city is determined by the 
fact that B cells take up Ag through surface Ig expression (BCR) and present this in class II 
to recruit T cell help (A). In the T cell independent response, specifi c B cells will be activated 
through local cytokines, in combination with an Ag-specifi c activation signal through the B 
cell receptor (B). 
More recently it has become clear that APC can also have a direct role in B cell activation. In 
a three cell model of B cells, T cells and APC, the latter cell type can deliver both contact and 
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soluble mediators to the CD40-activated B cells (C). In the T cell independent route, activated 
APC, for instance through TLR signalling, increase their expression of TNF family members 
BAFF and APRIL. These ligands show a complex interaction with three potential receptors 
expressed on B cells: TACI, BCMA and BAFF-R. In combination with cross-linking of B cell 
receptors, these signals can regulate IgA switch and differentiation into antibody producing 
cells (D).
express the surface marker langerin and CD1a are located mainly in epithelial 
layers. Toll Like Receptor (TLR) signalling interstitial DC, expressing the 
C-type lectin DC-SIGN and/or the blood dendritic cell antigen 1 (BDCA-1) 
are located in the dermis and in most peripheral organs. Plasmacytoid DC are 
characterized by expression of BDCA-2 and not only present in lymphoid 
organs, close to high endothelial venules, but are also attracted to sites of 
infl ammation [73-75]. These two different subsets of DC, myeloid derived 
DC and plasmacytoid DC, have different functions, that are only partially 
characterized, and might be dependent on the activation status and the 
localisation of the DC [70].
5.3  Role of DC and B cell activation
As mentioned above, regulation of IgA production can occur both in a T cell 
dependent and a T cell independent manner. In both cases, DC seem to have 
a critical role (Figure 2). DC can induce an immune reaction by presenting 
antigens to T cells, leading to activation of B cells. The interaction between 
B cells and T cells has been studied extensively and is mainly dependent on 
MHC and the CD40-CD40-ligand interaction [76]. Upon activation DC can 
produce several chemokines, leading to recruitment of B cells to the place of 
infl ammation [77]. 
 Next to this T cell dependent effect of DC on B cells, there is a direct 
interaction between B cells and DC, which is T cell independent. This has 
been shown in an in vitro model, in which in vitro generated DC were co-
cultured with B cells in the presence of a CD40L transfected cell line [78;79]. 
Addition of in vitro generated DC to human B cells resulted in a three to 
six fold increase in the recovery of viable B cells within a week [80]. In the 
cultures DC and B cells cluster and in the presence of IL-10 and TGF-β, DC 
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skewed isotype switching of naïve B cells towards IgA1 and IgA2 producing 
plasma cells [79]. Which factor or factors are responsible for the direct effect 
of DC on B cells is unknown. DC produce several cytokines like IL-12, and 
the IL-12R is, although expressed in the main human B-cell subsets, functional 
in naïve B-cells [81]. 
 The TNF superfamily member B lymphocyte stimulator (BlyS) also 
known as BAFF is known to promote B cell survival and differentiation. BlyS 
is expressed on most myeloid cells, including DC and could be the cytokine 
by which DC regulate B cell function [82-84].
 Other factors by which DC can have a direct effect on B cells are 
retinoic acid (RA) which acts in a synergistic way with interleukin-6 (IL-6) 
or IL-5. In mice intestinal DC induced T cell-independent expression of IgA 
and gut-homing receptors on B cells [85].
6.  Scope of the thesis
IgAN is a complex disease. The present thesis investigates the possible 
contribution of various players of the immune response in the pathogenesis of 
IgAN. As the regulation of the IgA immune response in IgAN patients seems 
to be disturbed and is likely to be involved in the pathogenesis of IgAN, we 
focussed on various components of the immune response. In particular we 
have focussed on DC in primary immune responses in IgAN. Immunization 
studies in IgAN patients have shown confl icting results. Both hyper and hypo 
IgA responses have been reported, dependent on the antigen used and the route 
of immunization. In chapter 2 we describe a study in which IgAN patients are 
simultaneously immunized with two neo-antigens via two different routes. 
The differences in the immune response are studied in a quantitative and in a 
qualitative manner. IgAN patients appeared to have a clear IgA hypo response 
after nasal immunization as compared with controls. We postulated that the 
observed differences in IgA production could be caused by either different 
numbers of mucosal DC or by changes in different subsets of DC in IgAN 
patients. 
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In chapter 3 we describe an immuno-histological analysis of nasal biopsies 
from IgAN patients and controls. The nasal biopsies were studied for the 
presence of DC and different subsets of DC. As the number of mucosal DC 
in IgAN patients appeared not to be lower than in controls, we postulated 
that the DC could be less effective in inducing an IgA immune response. 
Therefore we studied in an in vitro system whether DC of IgAN patients 
differ in their capacity to induce IgA production by naïve B cells. This study 
is described in chapter 4. It was found that DC from IgAN patients are less 
effective in inducing IgA production in naïve B cells. These studies suggest 
that DC surface molecules are responsible for the difference in IgA production 
that was found between IgAN patients and controls. 
 IgA deposits in IgAN consist mainly of polymeric IgA1. Moreover in 
a minority of cases SIgA can be detected in mesangial deposits. As SIgA 
is colocalized with MBL and associated with more hematuria and more 
proteinuria, SIgA might have a pathogenic role in the development of IgAN. 
Chapter 5 is a general review on the role of SIgA in IgAN. In chapter 6 we 
describe the size distribution of antigen-specifi c IgA after immunization 
in IgAN patients and in control persons. Both mucosally induced and 
systemically induced immune responses were studied in IgAN patients and 
in controls. Besides we investigated whether antigen-specifi c SIgA could be 
detected in the circulation, after mucosal immunization. It appeared that the 
size distribution of antigen-specifi c IgA was mainly polymeric. No differences 
between patients and controls were observed. In both groups we were able to 
detect low concentrations of antigen-specifi c SIgA in the circulation.
 The glycosylation pattern of IgA in IgAN patients differs from the 
normal glycosylation pattern of IgA and is also very likely to be involved in 
the pathogenesis of IgAN. Since the function of IgA is strongly determined 
by its glycosylation pattern, and since additional recent information on this 
issue was published, chapter 7 summarizes and discusses these fi ndings in the 
context of the studies described in the recent thesis. 
 Finally chapter 8 summarizes the different studies and outlines the 
relevance of these studies in the context of the pathogenesis of IgAN.
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Summary
Twelve IgA nephropathy (IgAN) patients and 18 controls were immunized 
with novel protein antigens, cholera toxin subunit B (CTB) via the nasal route 
and keyhole limpet hemocyanin(KLH) subcutaneously. Antibody secreting 
cells and antibody response in body fl uids were determined by ELISPOT assay 
and ELISA, respectively. Analysis of variance showed, in contrast to controls 
(p<0.001), no CTB-specifi c IgA response in the nasal washes of patients with 
IgAN. Signifi cantly lower numbers of CTB-specifi c antibody-secreting cells 
in peripheral blood (p<0.001)and CTB-specifi c antibodies in plasma (p<0.005)
were found in IgAN, both restricted to the IgAl subclass. The proportions 
of CTB-specifi c IgAl-secreting cells in bone marrow aspirates correlated 
signifi cantly with the corresponding ratios in plasma, with signifi cantly lower 
values (p<0.005)in IgAN as compared to controls. These results support the 
existence of a ‘mucosa-bone marrow axis’ in humans, but no dysregulation 
of this axis was found in IgAN. The defi cient mucosal IgA immune response 
to CTB observed in this study after primary mucosal immunization indicates 
that patients with IgAN have a defective immune response when challenged 
intranasally. These patients may depend on more frequent and/or prolonged 
antigen encounter at mucosal sites before effi cient mucosal immunity is 
established. Repeated seeding of antigen-specifi c cells to secondary lympoid 
organs could result secondarily in the relative hyperresponsiveness found in 
IgAN upon reactivation by parenteral immunization.
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Introduction
Primary IgA nephropathy (IgAN) is a common form of primary 
glomerulonephritis with a varied spectrum of clinical presentations, leading 
to progressive renal failure in a substantial proportion of patients [1;2]. The 
disease is characterized by deposits of IgAl in the glomerular mesangium 
[3-8]. The mesangial IgA has been found to consist at least in part of 
polymeric IgA (p-IgA) [5;9-11]. Although increased plasma levels of IgAl 
and IgAl-containing immune complexes are thought to be of pathogenetic 
importance, the mechanism of the mesangial deposition remains unclear 
[12]. The increased concentration of plasma IgAl appears to be the result 
of an increased production of this isotype by the bone marrow [13-16]. The 
macromolecular IgA found in the circulation also contains predominantly 
monomeric IgAl (m-lgA1) [17;18]. The pathogenetic signifi cance of p-lgA 
in IgAN is still subject of controversy. In children p-IgA levels correlate with 
bouts of macroscopic hematuria [19;20], but in adults the elevation of serum 
p-IgA and its correlation with disease activity is less clear [5;6;15,21-27].
 Although it seems obvious that the stimulus for IgA production is of 
mucosal origin, the responsible agent in IgAN and the site of immunization 
remain to be elucidated. On the basis of the association of episodes of 
macroscopic hematuria with infections of mainly the upper respiratory tract 
[1], it is assumed that in IgAN the mucosal immune system is stimulated 
by microbial antigens. However, previous studies of IgA responses, both 
after systemic and oral secondary immunization, in patients with IgAN have 
provided confl icting results [28-34]. The mucosal immune response after 
nasal immunization with novel or recall (viral)antigens has not been studied 
in patients with IgAN.
 Systemic immunization in humans results in the transient appearance 
in the peripheral blood of B cells capable of spontaneous antigen-specifi c 
antibody production [35-37]. These anti-body-secreting cells are considered 
to represent migrating B cells on their way to their fi nal destination in systemic 
lymphoid tissues, including lymph nodes, spleen and bone marrow [38]. The 
appearance of antigen-specifi c antibody-secreting cells is followed by a rise 
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in specifi c serum antibodies produced mainly by bone marrow plasmocytes 
[38]. Antigen-specifi c antibody-secreting cells in peripheral blood have also 
been detected after intranasal immunization [39-41], extending the evidence 
for the concept of a common mucosal immune system [42;43]. According 
to this concept, B cells activated at mucosal inductive sites, migrate via the 
circulation to local but also to remote mucosal effector sites, where they 
undergo fi nal differentiation into plasmocytes.
 Exposure of a mucosal surface to non-viable or live microbial antigens 
(vaccines or infection) may result in a local and a systemic immune response. 
Except for live antigens, an IgA response is not regularly induced in the 
systemic compartment [44]. Cholera toxin and its B subunit (CTB) have been 
shown to induce not only strong mucosal IgA responses but also serum IgA 
(and IgG) antibodies [45]. This is explained by the ability of the B subunit to 
bind avidly to GM 1 ganglioside, its natural ligand present on microfold cells 
overlying the mucosa associated lymphoid tissue (MALT) [46].
 The routes of immunization and types of antigens that might induce 
an effective immune response in the human bone marrow have not been 
clarifi ed. Repeated exposure to mucosal antigens may induce B-cells to 
migrate to mucosal and non-mucosal lymphoid tissues such as the lymph 
nodes and spleen [47]. Upon rechallenge, memory B cells may leave the 
lymph nodes and disseminate the secondary response to the bone marrow 
where they differentiate into plasma cells that secrete p-IgA antibodies [30]. 
The existence of such a ‘mucosa-bone marrow axis’ is suggested by studies 
in experimental animals [48-50]. However, there are no data available yet to 
support this axis in humans.
 The high IgAl serum levels in patients with IgAN could either be a primary 
hyper-responsiveness of the mucosal immune system or a compensatory 
reaction of the systemic compartment to a hypothetical hyporesponsivity of 
the MALT. To investigate the hypothesis of a dysregulated ‘mucosa-bone 
marrow axis’ in patients with primary IgA nephropathy we studied the immune 
response in both compartments of the IgA immune system after primary and 
booster intranasal immunization. This study indicates that patients with IgAN 
are not hyper- but hyporesponders when they are immunized intranasally with 
CTB.
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Materials and methods
Human subjects
The study protocol was approved by the Ethical Committee of the Leiden 
University Hospital. All individuals gave informed consent. Twelve patients 
(11 males, mean age 36.5 years; range 26 to 52 years) with biopsy proven 
IgAN were studied. None of the patients had clinical or laboratory evidence 
of Henoch-Schönlein purpura, systemic lupus erythematosus, liver disease 
or received immunosuppressive therapy. Kidney function was normal or 
mildly impaired (creatinine clearance >80ml/mim). None of the patients had 
macroscopic hematuria or proteinuria >2g/24hours. As controls 18 healthy 
volunteers, (12 males, mean age 28.4 years; range 21 to 40 years) were 
recruited. Neither patients nor controls had received the whole cell/B subunit, 
parenteral whole cell cholera vaccine or had had clinical cholera previously. 
There were no symptoms or signs of mucosal infection in the two weeks 
preceding or during the study period. All subjects completed the study.
Immunization protocol
Individuals were given 0.33 mg of recombinant CTB (provided by JH) [37] 
per immunization intranasally by spray and 250 μg KLH (Calbiochem, La 
Jolla, CA, USA) subcutaneously. Two identical doses of CTB and KLH 
were given as booster immunization on days 14 and 28, respectively. Serum 
samples and peripheral blood mononuclear cells (PBMC) were obtained on 
days 0, 7, 21, 35 and 42. Two weeks after the second booster immunisation 
(day 42) bone marrow samples were obtained from the posterior iliac crest 
[13]. Nasal washes were collected on days0, 7, 21 and 35. Both antigens were 
well tolerated and no side-effects were noted.
Cells
Venous blood was collected in sterile, heparinized syringes. PBMCs were 
isolated by centrifugation using a standard Ficoll-Hypaque (Sigma Chemical 
Co., St. Louis, MO, USA) density gradient. Bone marrow nucleated cells 
(BMNC) were processed as previously described [13]. After lysis of 
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contaminating red blood cells and three washings, the cells were placed in 
complete tissue culture media consisting of RPMI 1640 medium supplemented 
with L-glutamine (Gibco, Breda, The Netherlands) and 10% heat-inactivated 
fetal calf serum (∆FCS) at a concentration of 5 x 106 cells/ml. The number of 
viable cells was established by trypan blue exclusion in a hemocytometer. The 
immunoglobulin-producing cells were assayed immediately in the enzyme-
linked immunospot (ELISPOT) assay.
Body fl uids
Serum samples were obtained from fresh venous blood after overnight fast. 
At the same time nasal wash effl uent was collected after installation of 3 x 1 
ml of sterile normal saline into each nostril with the neck extended, remaining 
still for one minute. Samples were immediately placed on ice, centrifuged 
(1200 rpm for 10 min at 4°C) and the supernatants collected. Samples were 
stored frozen at -20°C until assayed.
ELISPOT assay
Total immunoglobulin and antigen-specifi c antibody-secreting cells were 
enumerated using the ELISPOT technique as described previously [51]. For the 
enumeration of immunoglobulin-secreting cells, the wells of nitrocellulose-
bottomed, 96-well Millititer HA plates (Millipore, Bedford, MA, USA) were 
coated with heavy chain specifi c, affi nity purifi ed goat F(ab’)2 fragments 
against human IgA, IgG or IgM (Jackson, West Grove, PA, USA). The capture 
antibodies for enumeration of immunoglobulin-producing cells of the two 
IgA subclasses were mAb 69-11.4 (specifi c for IgAl) and mAb 16-512-H5 
(specifi c for IgA2). The quality, specifi city and general usefulness in different 
body fl uids of these mAbs has been described [5;52;53].
 Purifi ed CTB (5 μg/ml) and KLH (20 μg/ml) were used as the coating 
reagents in the antigen-specifi c ELISPOT. For the detection of CTB-specifi c 
antibody-secreting cells, individual wells of the Millititer HA plates were 
precoated with 100 μl of 6 μM GM1 ganglioside (Sigma) in phosphate 
buffered saline, pH 7.4 (PBS) overnight at 4°C. GM1 precoated wells were 
subsequently coated with 100 μl of CTB overnight at 25°C. The next day 
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remaining binding sites were saturated with 150 μl of culture medium 
containing 10% ∆FCS for two hours at 37°C in a humidifi ed atmosphere with 
5% CO2. Between the different incubations the wells were washed three times 
and soaked for at least fi ve minutes using sterile PBS. After discarding the 
blocking solution, 100 μl of cell suspension was dispensed into the wells at 
four different cell densities (range, 6.25 · 105/ml to 5 · 106/ml) in duplicate. 
After incubating the cells for four hours at 37°C and 5% C02, the plate was 
washed three times with PBS and three times with PBS containing 0.05% 
Tween 20 (PBST). Biotinylated heavy chain-specifi c, affi nity purifi ed F(ab')2 
fragments against human IgA, IgG or IgM (Tago, Burlingame, CA, USA), 
appropriately diluted, were added as secondary antibody.
 Antigen-specifi c antibodies of the IgA subclasses were detected by 
mAb 69-11.4 (for IgAl) and mAb 16-512-H5 (for IgA2). After overnight 
incubation at 4°C the wells containing the mAbs were incubated with affi nity 
purifi ed, biotinylated goat anti-mouse IgG for two hours at 37°C. After 
washing and soaking with PBST six times, extravidin-conjugated alkaline 
phosphatase (Sigma) was added to the wells to bind the secondary antibody 
for 60 minutes at room temperature. Following a fi nal wash (PBST and PBS 3 
times, respectively) and soak in PBS the nitrocellulose-bottomed wells were 
exposed to a chromogen substrate solution consisting of 5-bromo-4-chloro-3-
indolyl phosphate toluidine salt (BCIP; Bio-Rad Lab, Richmond, CA, USA) 
and p-nitroblue tetrazolium chloride (NBT; Bio-Rad) in 0.1 M NaHCO3 
plus 1 mM MgCl2, pH9.8. When spots reached maximal intensity, generally 
between 45 and 60 minutes, the reaction was stopped by thoroughly rinsing 
the plates with water. Spots were counted under a stereomicroscope with 
x 40 magnifi cation and expressed as number of spot-forming cells (SFC) 
per 106 PBMCs or BMNCs added to the wells. Appropriate control wells 
(GM1 ganglioside, culture medium, irrelevant antigen) showed no spots. In 
preliminary experiments we determined the optimal intranasal dose of CTB 
needed to induce the appearance of CTB-specifi c ASC. In a group of fi ve 
volunteers a dose of either 0.33 or 1 mg induced an apparently maximal 
response with a peak between fi ve and nine days. Based on these data we 
selected a dose of 0.33 mg CTB for nasal immunization and a sampling period 
of seven days [43] after each immunization.
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ELISA
Plasma and nasal washes were tested for total and antigen-specifi c antibodies 
of the various isotypes by enzyme-linked immunosorbent assay (ELISA). 
Polystyrene 96-well ELISA plates (Greiner, Alphen a/d Rijn, The Netherlands) 
were coated, overnight at room temperature, with 100 μl/well of the capturing 
antibody, appropriately diluted in PBS. Reagents were heavy chain specifi c, 
affi nity purifi ed goat F(ab’)2 fragments against human IgA, IgG or IgM 
(Jackson, West Grove, PA, USA). In the IgA subclass ELISA the primary 
antibodies were subclass specifi c mAb 69-11.4 (IgAl) and 16-512-H5 (IgA2). 
In the CTB-specifi c ELISA the polystyrene plates were coated with 100 μl 
of CTB (2.5 μg/mI) or KLH (10 μg/ml) overnight at room temperature. After 
three washings with PBST, non-specifi c binding sites were blocked with 
PBST containing 1% bovine serum albumin.
 Appropriate serial dilutions of serum or nasal wash samples were added 
to duplicate wells and incubated for two hours at 37°C. Samples obtained at 
the different time points after immunization were investigated in the same 
ELISA plate. Nasal wash anti-CTB antibody levels were corrected for the 
infl uence of dilution, which occurred when the specimen was obtained, by 
dividing the antibody level by the total level of the corresponding isotype 
by ELISA or the albumin concentration as determined by rate nephelometry 
(Array Rate Nephelometer; Beckman, Brea, CA, USA). In the ELISA for 
total immunoglobulin serial two fold dilutions of a normal human serum pool 
(NHS) with known concentrations of IgA, IgAl, IgA2, IgG and IgM served 
as a standard [53]. In the vaccine-specifi c ELISA’s titers were expressed in 
arbitrary units per ml (AU/ml), relative to a standard serum yielding high 
optical density (OD) values in ELISA for a certain isotype. A different 
standard serum was chosen for each isotype and used in a dilution series on 
each EL1SA plate. The standard sera yielded increasing OD values in a dose 
dependent fashion to values usually over 2.000.
 Bound total immunoglobulin was detected by heavy chain-specifi c, 
affi nity-purifi ed goat F(ab’)2 fragments against human IgA (for lgA, IgAl and 
lgA2), lgG and IgM coupled to biotin (Tago). Vaccine-specifi c antibodies 
were detected by optimal dilutions of biotinylated goat anti-human IgA, 
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IgG, IgM (Tago) and mAb 69-11.4 (IgAl) or mAb 16-512-H5 (IgA2) as 
secondary antibodies and incubated for two hours at 37°C. The anti-IgA 
subclass mAbs were detected by biotinylated, affinity-purified goat anti-
mouse IgG. Consecutive incubations followed with streptavidine conjugated 
to horseradish peroxidase (Zymed; Sanbio BV, Uden, The Netherlands) and 
enzyme substrate (2,2’-azino-bis [3-ethylbenzthiazoline-6-sulfonic acid]; 
Sigma) containing 0,0075% H202. Between each step the wells were washed 
three times (PBST).
 Optical density (OD) was measured at 415 nm on a microplate reader 
(Bio-Kinetics Reader EL 312e, Biotek Instruments Inc., Winooski, VT, USA). 
Concentrations or titers were obtained by interpolation on the standard curves 
using a four parameter modeling procedure (KinetiCalc, EIA Application 
Software). The final concentrations in each sample were calculated as the 
mean of the results at the proper sample dilutions yielding ODs in the linear 
parts of the calibration curves.
Statistical analysis
All statistical calculations were performed using the SPSS for Windows 
Release 6.0 software package. The ELISA-titers and the SFC-numbers 
showed a skewed distribution and were transformed logarithmically prior to 
analysis. The two way ANOVA with repeated measurements was used to study 
the effect of both group (patient vs. control) and time after immunization. 
Post hoc comparisons were made using Scheffe’s procedure. Simple linear 
regression was used to determine correlation between the number of SFC and 
antibody concentrations or titers. Significance was accepted at the 0.05 level. 
Results are expressed as geometrical mean ±SEM.
Results
Antibody in nasal washes after intranasal immunization
The CTB-specific IgA antibody response in nasal washes after intranasal 
immunization was determined by specific ELISA. Samples obtained at the 
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different time points for each subject were examined in the same ELISA plate 
relative to an internal standard and expressed in arbitrary units per ml (AU/ml). 
Pre-immunization titers of CTB-specifi c IgA were all in the lower linear parts 
of the standard curves and not signifi cantly different between the two groups. 
The local IgA immune response after immunization for each individual was 
defi ned as the fold increase in titer relative to baseline.
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Figure 1. CTB-specifi c IgA immune response in nasal wash. IgA immune response in nasal 
wash effl uents of patients with IgAN (?) and controls(?) following immunization with CTB 
intranasally on days 0, 14 and 28. Response is defi ned as the fold increase in the ratio of 
CTB-specifi c IgA titer/total IgA1 (AU/μl) relative to the preimmunization ratio. Results are 
expressed as geometrical means ±SEM, and showed a defi cient local immune response in 
patients with IgAN, reaching signifi cance (**p<0.0005) following the third immunization as 
compared to controls. No signifi cant differences were found with respect to the total IgA1/
albumin ratios (μg/μg) between groups or with time, indicating results were not biased by 
dilutional differences in obtaining the specimen.
To standardize for dilutional differences in obtaining the specimen, the titers 
of CTB-specifi c IgA antibodies (AU/ml) in the nasal washes were related to 
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the corresponding concentration of total IgA (μg/ml). The IgAl-anti CTB over 
total IgAl ratio (AU/μg) after each challenge relative to pre-immunization 
values is plotted against time in Figure 1. In contrast to controls, patients 
with IgAN showed no local IgA immune respons after the fi rst (day 14) and 
second (day 28) rechallenge. This difference was signifi cant (p<0.0005) after 
the second rechallenge as compared to controls. The total IgA over albumin 
ratios did not vary signifi cantly in time and no signifi cant differences between 
the two groups were found (Figure 1). This indicated that the results were not 
biased by the method used to standardize for differences in dilution, occurring 
when samples were obtained.
Circulating anibody-secreting cells after subcutaneous or 
intranasal immunization
The frequencies of antigen-specifi c spot forming cells (SFC) occurring 
in peripheral blood were measured before and after intranasal (CTB) and 
subcutaneous (KLH) immunization in patients with IgAN and controls by 
ELISPOT assays.
 The numbers of SFCs per 106 PBMC are plotted against time for CTB in 
Figure 2 and for KLH in Figure 3. Analysis of variance revealed a signifi cant 
(p<0.0001) increase in the numbers of specifi c IgM, IgG, IgA, IgAl and IgA2 
SFCs in peripheral blood both after intranasal immunization with CTB (Figure 
2) and subcutaneous immunization with KLH (Figure 3).
 After primary intranasal immunization with CTB the numbers of CTB-
specifi c IgM or IgG SFCs were not signifi cantly different between patients 
and controls (p=0.85 and p=0.23, respectively). However, the number 
of CTB-specifi c lgA SFCs was signifi cantly (p<0.005) lower in patients. 
The number of CTB-specifi c SFCs of the IgAl subclass was signifi cantly 
(p<0.0001) lower in patients, while no signifi cant (p=0.84) difference was 
found between the groups with respect to CTB-specifi c SFC of the lgA2 
subclass. The number of CTB-specifi c IgA2 SFCs rose signifi cantly in time, 
but was strikingly low compared to the IgAl response in controls. The IgAl-
ratio (IgAl/{IgAl+IgA2}) in patients was also signifi cantly (p<0.005) lower 
in patients. Comparable results were found after the fi rst and second booster 
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immunization (Figure 2). Since peak responses have been shown to occur 
earlier after booster immunization [54], our results obtained after the second 
(day 21) and third (day 35) dose probably refl ect the descending limb of the 
immune response.
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Figure 2. Nasal immunization with CTB. Frequencies of IgM (left panels, ?), IgG (left 
panels, ?), IgA (left panels, ?), IgAl (right panels, ?) and IgA2 (right panels, ?) isotypes 
of CTB-specifi c spot forming cells (SFCs) in controls and patients with IgAN measured in 
PBMCs isolated before immunization or seven days following each immunization with CTB 
intranasally on days 0, 14 and 28. The ratios (●) of IgAl SFCs over {IgAl + IgA2} SFCs 
are also shown in the right panels. Results, expressed as geometrical means ±SEM, showed 
signifi cantly (p<0.0001) lower numbers of CTB-specifi c SFCs inpatients with IgAN, restricted 
to the IgAl subclass. p values from Scheffe’s procedure are *p<0.05, **p< 0.005).
After primary subcutaneous immunization with KLH the numbers of KLH-
specifi c IgM (p=0.27), lgG (p=0.13), IgA (p=0.93), IgAl (p=0.81) and IgA2 
(p=0.26) SFCs were not signifi cantly different between patients and controls. 
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Subsequent booster immunizations also yielded no signifi cant differences in 
the numbers of KLH-specifi c SFCs between the two groups (Figure 3).
 The numbers of total immunoglobulin secreting cells of the different 
isotypes showed no signifi cant differences between patients and controls 
during the course of time (Figure 4).
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Figure 3. Subcutaneous immunization with KLH. Frequencies of IgM (left panels, ?), IgG 
(left panels, ?), IgA (left panels, ?), IgAl (right panels, ?) and IgA2 (right panels, ?) isotypes 
of KLH- specifi c spot forming cells (SFCs) in controls and patients with IgAN measured in 
PBMCs isolated before immunization or seven days following each immunization with KLH 
subcutaneously on days 0, 14 and 28. The ratios (●) of IgAl SFCs over {IgAl +IgA2} SFCs 
is also shown in the right panels. Results, expressed as geometrical means ±SEM, showed no 
signifi cant differences in KLH-specifi c SFCs of the various isotypes between patients with 
IgAN and controls.
Specifi c antibodies in plasma after systemic or intranasal immunization
The antigen-specifi c antibody response in plasma after intranasal (CTB) and 
subcutaneous (KLH) immunization was determined by specifi c ELISAs. 
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Samples obtained at the different time points for each subject were examined 
in the same ELISA plate relative to an internal standard and expressed in 
arbitrary units per ml (AU/ml). Pre-immunization titers of CTB-specifi c and 
KLH-specifi c isotypes were all in the lower linear parts of the standard curves 
and not signifi cantly different between the two groups. The antibody titers for 
each individual was expressed as the fold increase in titer relative to baseline 
and plotted against time.
 Analysis of variance showed a signifi cant (p<0.0001) increase in the 
IgG, IgA (Figure 5) and IgAl (Figure 6) titers against both CTB and KLH 
after intranasal and subcutaneous immunization, respectively.
2000
1500
1000
500
0
SF
C
/1
06
 P
B
M
C
Isotypes IgA subclasses
2000
1500
1000
500
0
SF
C
/1
06
 P
B
M
C
0 1 3 5
Time, weeks
IgAN
Control
100
75
50
25
0
IgA
1 ratio, %
1000
750
500
250
0
IgA
1 ratio, %
0 1 3 5
Time, weeks
1000
750
500
250
0
100
75
50
25
0
Figure 4. Total immunoglobulin secreting cells. Frequencies of total IgM (left panels, ?), 
IgG (left panels, ?), IgA (left panels, ?), IgAl (right panels, ?) and IgA2 (right panels, ?) spot 
forming cells (SFCs) in controls and patients with IgAN measured in PBMCs isolated before 
immunization or seven days following each immunization on days 0, 14 and 28. The ratios (●)
of IgAl SFCs over {IgAl + lgA2} SFCs is also shown in the right panels. Results, expressed 
as geometrical means ±SEM, showed no signifi cant differences in immunoglobulin-secreting 
cells of the various isotypes between patients with IgAN and controls.
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Comparison between the two groups showed a signifi cantly (p<0.001) lower 
CTB-specifi c IgA immune response in plasma after nasal immunization in 
patients with IgAN (Figure 5). The CTB-specifi c IgAl immune response 
was also found to be signifi cantly (p<0.005) lower in patients (Figure 6). No 
differences were found between the groups with respect to the CTB-specifi c 
IgM, IgG and IgA2 immune responses.
After subcutaneous immunization with KLH no signifi cant differences were 
found in the KLH-specifi c immune responses between patients and controls. 
The results for IgA and IgG are plotted against time in Figure 5.
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Figure 5. Antigen-specifi c immune response in plasma. Specifi c IgA (left panels) and IgG 
(right panels) immune response in plasma of patients with IgAN (●)and controls (?) following 
immunization with CTB (intranasal) and KLH (subcutaneous) on days 0, 14, 28. Response 
defi ned as fold increase in titer (AU/ml) relative to preimmunization. Results, expressed as 
geometrical means ±SEM, showed a signifi cantly (p<0.001) lower CTB-specifi c IgA immune 
response in plasma in patients with IgAN as compared to volunteers. No signifi cant differences 
were found between the groups with respect to the CTB-specifi c IgG and KLH-specifi c IgA 
and IgG responses. (P-values from Scheffe’s procedure are *p<0.05, **p<0.005).
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Correlation between ASC in bone marrow and antibodies in plasma
Correlation between the number of total immunoglobulin and CTB-specifi c 
SFCs in bone marrow aspirates and the corresponding concentration or titer in 
plasma was examined two weeks after the last immunization (day 42). At this 
time virtually no CTB-specifi c SFCs were found in the peripheral blood. The 
lack of correlation between PBMC and BMNC indicated that there was no 
signifi cant contamination of the bone marrow aspirates by peripheral blood.
 Analysis by simple linear regression showed that there was a signifi cant 
correlation between the number of IgA (r=0.67; p<0.005) and IgAl (r=0.76; 
p<0.001) SFCs in the bone marrow (ELISPOT) and the concentration of IgA 
and IgAl in plasma (ELISA) on day 42, respectively. Patients with IgAN had 
signifi cantly higher numbers of total IgA (p<0.05) and IgAl (p<0.01) SFCs in 
bone marrow aspirates and signifi cantly higher concentrations of IgA (p<0.01) 
and IgAl (p<0.005) in plasma. These results are shown in Figure 7A.
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Figure 6. CTB-specifi c IgAl immune response in plasma. IgA1 immune response in plasma 
of patients with IgAN (●) and controls (?) following immunization with CTB intranasally on 
days 0, 14, 28. Response defi ned as fold increase in titer (AU/ml) relative to preimmunization. 
Results, expressed as geometrical means ±SEM, showed a signifi cantly (p<0.001) lower CTB-
specifi c IgAl immune response in patients with IgAN. p values from Scheffe’s procedure are 
*p<0.05.
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There was also a signifi cant correlation between the proportion (SFC/SFC) 
of IgA-antiCTB/total-lgA (r=0.68; p<0.001) and lgAl-antiCTB/total-IgAl 
(r=0.62; p<0.001) in the bone marrow (ELISPOT) and the IgA-antiCTB/
total-IgA and IgAl-antiCTB/total-IgAl ratios (AU/μg) in plasma (ELISA) on 
day 42. Patients with IgAN had signifi cantly lower ratios of CTB-specifi c 
IgA/total-IgA (p<0.05) and CTB-specifi c lgA/total-IgAl (p<0.005) in bone 
marrow aspirates, and also signifi cantly lower ratios of IgA-antiCTB/total-
IgA (p<0.005) and IgAl-antiCTB/total-IgAl (p<0.005) in plasma. These 
results are shown in Figure 7B.
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Figure 7. Correlation between bone marrow and plasma after nasal immunization. (A) 
Correlation between the number of total IgA (r=0.67, p<0.005) or IgAl (r=0.76, p<0.001) 
SFCs in bone marrow aspirates (SF/l06 BMNC) and plasma concentration of IgA or IgAl (μg/
ml) two weeks after the last immunization. Results (transformed to their natural logarithms) 
showing signifi cant correlation between bone marrow and plasma, with signifi cantly higher 
total IgA and IgAl (p<0.01)values in IgAN (●), both in bone marrow aspirates and plasma. (B) 
Correlation between IgA-anti-CTB/total-IgA (r=0.68, p<0.001)and IgAl-anti-CTB/total-IgAl 
(r=0.62, p<0.001)ratios (SFC/SFC) in bone marrow aspirates and corresponding ratios (AU/
μg) in plasma. Results (natural logarithms) showed signifi cantly (p<0.005) lower CTB-specifi c 
IgA and IgAl values in patients with IgAN (●), both in bone marrow aspirates and plasma.
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Discussion
Elevated plasma levels of IgAl are thought to play an essential role in 
the pathogenesis of IgAN [14], and are the consequence of an increased 
production, in which the bone marrow may be the predominant site [13;15;16]. 
The clinical association of exacerbations of the disease with upper respiratory 
tract infections suggests that the trigger for the increased IgAl production 
is frequently in the nasopharynx [1]. Furthermore, a signifi cantly higher 
proportion of IgAl-producing cells was found in the tonsils of patients with 
IgAN [55-57]. In contrast, the histology, the percentage of IgA plasma cells, 
and the IgA subclass distribution in the small bowel were found to be normal 
[58;59] or showed a reduced percentage of IgA plasma cells [60] as compared 
to controls. However, it is still unclear how upper respiratory infections can 
induce an overproduction of IgAl in the bone marrow of IgAN patients. Such 
a sequence of events would require a link between the mucosal and systemic 
compartments of the IgA immune system through a hypothetical “mucosa-
bone marrow axis” [13;15]. Evidence for the existence of such an axis has so 
far only been reported in experimental animals [48-50].
 The present study is the fi rst, to our knowledge, to provide evidence for 
the existence of a mucosa-hone marrow axis in humans. Both in the healthy 
controls, and in the IgAN patients we have demonstrated in this study the 
presence of specifi c IgAl antibody-producing cells in the bone marrow after 
nasal antigen presentation. This suggests that mucosal presentation of antigens 
in humans not only leads to a dissemination of the immune response to distant 
mucosal sites as defi ned in the concept of the common mucosal immune system 
[42;43] but also to the systemic compartment of the IgA system, especially 
the bone marrow, the predominant site of plasma IgA production in humans 
[61]. In the current study we chose CTB as the antigen because of its strong 
immunogenicity. Apart from a small previous study [37], this is the fi rst study 
demonstrating the good mucosal immunogenicity of nasal immunization with 
CTB in humans. The frequency of responders (>4-fold increment in plasma 
titer) in the control group was 16%, 94% and 100% after the fi rst, second and 
third immunization, respectively. The CTB-specifi c secretory IgA response 
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in controls was almost exclusively of the IgAl subclass as was described 
previously for serum antibodies after oral immunization with CTB [54]. 
Such an antigen would provide us the best opportunity to demonstrate the 
communication of a mucosal antigen presentation to a bone marrow immune 
response.
 In the light of previous immunization studies in IgAN patients, which 
have provided evidence of both a normal [29;31;33;34]and an increased 
[30-32] IgA immune response, sometimes limited to the relevant subclass 
IgAl [30] or polymeric forms [31], we had expected that the IgAl anti-CTB 
response would be higher in our patients than in the controls. Moreover, our 
hypothesis was that especially the immune response in the patients’ bone 
marrow after nasal immunization would be signifi cantly higher, refl ected by 
increased numbers of IgAl antibody-secreting cells, and increased levels of 
plasma IgAl antibodies. Surprisingly, we found signifi cantly lower immune 
responses in the IgAN patients, not only in the systemic compartment (bone 
marrow and plasma), but also locally in the nasal secretions, and in the transient 
circulating antibody secreting cells. Therefore no apparent dysregulation of 
the mucosa-bone marrow axis was found in patients with IgAN.
 As an internal control, all subjects were concurrently systemically 
immunized with KLH. In contrast to the decreased immune response to nasal 
CTB, the systemic immune response to parenteral KLH was not signifi cantly 
different in patients compared with healthy controls. These unexpected fi ndings 
raise the question why there is a discrepancy in the induced immune response 
to nasal CTB and parenteral KLH in patients in the present study, while some 
earlier studies with recall antigens using the oral [32] or parenteral [30;31] 
immunization route have suggested an exaggerated systemic IgA immune 
response in IgAN patients. A possible reason is that the antigens employed 
in the current study are both “neo-antigens” to which our subjects had in all 
probability not been previously exposed. This factor makes the current study 
different from the published immunization studies in which recall antigens 
were used. A hypothesis explaining the different fi ndings using neo-antigens 
could be that IgAN patients have a defi cient primary nasal immune response, 
resulting in a delayed activation of immunocompetent cells. Interestingly, 
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recall nasal priming with tetanus toxoid and subsequent parenteral boostering 
resulted in lower serum IgAl antibodies (and also a smaller increase) in IgAN 
patients before and after parenteral rechallenge [34]. An indication of IgA-
specifi c suppression after oral recall immunization has also been reported. 
Elevated serum IgA antibodies prior to immunization decreased to normal 
levels afterward, suggesting some degree of in vivo hyporesponsiveness in 
patients with IgAN [33]. Such a defi cient primary immune response may 
then lead to persistence or recurrence of the antigenic stimulus in patients, 
whereas healthy individuals succeed in effective elimination or exclusion 
of antigen. The resulting ongoing or repeated stimulation of the immune 
response may eventually lead to overproduction of IgA antibodies in the 
systemic compartment, and an increased number of memory cells. The 
previously reported increased IgA immune response to recall antigens may be 
the refl ection of this increased level of immunological memory [30-32].
 It is relevant to note that all of the earlier studies that found evidence for 
a signifi cantly higher systemic IgA [32] or IgA1 [30] immune response, also 
reported higher preimmunization levels in IgAN patients. When the peak levels 
of IgA antibodies after immunization are related to these already elevated 
baseline levels, the relative increase in titers is not augmented in patients 
[30]. The higher levels of naturally occurring antibodies to certain types of 
antigens and the high total serum IgA in IgAN suggest that a wide range 
of antigenic specifi cities are activated in these patients. The most consistent 
observation has been that the abnormalities in the IgA system in patients with 
IgAN are predominantly or exclusively restricted to the IgAl subclass. This 
restriction could be explained by the chemical nature of the immunogen, or a 
second explanation would be that the IgAl response is determined by the site 
of exposure to the antigen [44]. This would mean that patients with IgAN are 
more heavily exposed, in frequency or duration, to antigens that induce an 
IgAl antibody response. On the other hand, in IgAN, mucosal abnormalities 
have so far mainly been found in the oropharyngeal region [55-57].
 A third possibility is a selective dysregulation of IgAl-producing 
B-lymphocytes in patients with IgAN. It is tempting to speculate that the 
defi cient mucosal and systemic IgAl response we found in IgAN patients with 
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nasal CTB is the consequence of inadequate antigen presentation (such as by 
dendritic cells) or an abnormality in T-cell regulatory mechanisms governing 
the common mucosal immune system and seeding of primed B-cells to the 
systemic compartment.
In summary, the data indicate that patients with IgAN have a defi cient primary 
mucosal immune response to intranasally administered CTB, limited to the 
IgAl subclass. Future studies will have to show whether the current fi ndings 
also pertain to other antigens. Studies are in progress to elucidate whether 
there is a discrepancy between the induced mucosal and systemic IgA immune 
response to repeated nasal challenge by viral recall antigens in patients not 
primed by previous parenteral immunization.
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Summary
IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide. Intranasal vaccination of patients with IgAN has shown mucosal 
and systemic IgA hyporesponsiveness. Here we investigated whether this 
IgA hyporesponse in IgAN patients can be explained by reduced numbers or 
altered subset distribution of dendritic cells (DCs) in nasal mucosa. 
 Eighteen IgAN patients and 18 healthy volunteers were recruited for this 
study. Nasal biopsies were taken, after local anaesthesia, from the lower edge 
of the inferior turbinate. Staining for different subsets of DCs was performed, 
using specifi c monoclonal antibodies. To detect myeloid dendritic cells we 
used CD1a, DC-SIGN and BDCA-1 as a marker and for plasmacytoid DCs 
we used BDCA-2. DC-cell numbers in the epithelium and in lamina propria 
were counted separately and expressed as positively stained cells per mm2. 
 Both myeloid and plasmacytoid DC could be demonstrated in nasal 
biopsies. Quantifi cation showed that IgAN patients contained signifi cantly 
more DC-SIGN positive cells in the lamina propria compared to controls. 
In addition in IgAN patients we observed more CD1a positive cells in the 
epithelium. No differences in BDCA-1 and BDCA-2 positive cells were found 
between patients and controls. The number of positively stained cells in the 
epithelial layer correlated strongly with the number of positively stained cells 
in the lamina propria. 
 Patients with IgAN have higher numbers of CD1a positive cells in 
the epithelial layer and more DC-SIGN positive cells in the lamina propria. 
Therefore the earlier observed IgA hyporesponsiveness in IgAN patients after 
mucosal vaccination cannot be explained by lower numbers of nasal DCs.
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Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide [1-3]. The disease is characterized by depositions of IgA1 in the 
mesangium of the kidney [4]. Recurrence of IgAN after renal transplantation 
is very common, indicating that next to renal factors, specifi c characteristics 
of IgA itself (quantitative and/or qualitatively) play a role in the pathogenesis 
[5]. IgA serum titers are increased in 50% of the patients, but the fact that other 
diseases with higher serum IgA titers, like HIV infection, are not associated 
with IgA depositions in the kidney, shows that higher serum levels of IgA 
are not the only cause of IgAN [6;7]. Alternatively, qualitative alterations in 
IgA such as differences in glycosylation, are thought to contribute to disease 
pathogenesis [8;9].
 Although the pathogenesis of the disease is not clear, there are reasons 
to believe that immune responses at mucosal surfaces play an important role. 
This idea stems from the observation that an upper respiratory tract infection 
in about 40% of IgAN patients leads to aggravation of their complaints in the 
form of increased blood levels in urine (synpharyngitic hematuria) [10]. It has 
been proposed that tonsils are responsible for the increased IgA levels in the 
serum [11]. Retrospective studies suggest that tonsillectomy is correlated with 
a favourable clinical course of the disease [12]. Several immunization studies, 
using different antigens and different routes of administration have shown 
confl icting results [13;14]. Simultaneous mucosal and systemic vaccination 
in IgAN patients with two neoantigens lead to an impaired IgA response 
upon the mucosal challenge, whereas no differences were seen after systemic 
vaccination [15;16].
 Given the role of dendritic cells (DCs) as professional antigen 
presenting cells involved in the initiation of immune responses and antibody 
formation, there is some suggestion that aberrant DC function contributes to 
IgAN. Not only do they link innate and adaptive immunity, but DCs might 
also be decisive via the interaction with T and B cells for the induction of 
effector immune responses or tolerance [12;17;18]. DCs have a direct effect 
on B cells and can induce isotype switching and enhance immunoglobulin 
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production [19;21]. In the presence of CD40 activated naïve B cells, DC can 
skew isotype switching towards IgA [19]. Recently we have shown in an in 
vitro model that DC of IgAN patients induce less IgA production by naïve B 
cells compared to DC from control persons [22].
 Different subsets of DCs have been described, based on phenotypic 
characteristics. There are two major subsets of DCs, namely myeloid DCs 
and plasmacytoid DCs. The myeloid DCs are found at two sites in tissues: 
Langerhans cells, which express the surface marker langerin and CD1a are 
located mainly in the epithelial layer, and interstitial DCs, expressing the 
C-type lectin DC-SIGN and/or the blood dendritic cell antigen 1 (BDCA-1). 
Plasmacytoid DCs are characterized by expression of BDCA-2 and /or CD123 
[23-25]. These two different subsets of DCs have different functions, that 
are only partially characterized, and might be dependent on the activation 
status and the localisation of the DC [2;26]. In addition interactions between 
subsets of DCs and cells that are locally present, may determine the outcome 
of an immune response. The effect of the mucosal microenvironment on DC 
response, and thereby on IgA production is still unclear.
 Based on the described hyporesponsiveness upon mucosal challenge 
of IgAN patients, and the central role of DCs in initiating immune responses, 
and our observation that DC from patients with IgAN induce less production 
of IgA by B cells, we hypothesised that IgAN patients in addition might 
have reduced numbers of DCs or that IgAN patients may have an altered 
composition of certain DC subsets at mucosal sites. To answer this question, 
nasal biopsies of 18 IgAN patients and 18 control persons were stained for 
specifi c DC subset markers and the results analysed with respect to DC cell 
numbers and subset composition. 
Materials and methods
Selection of IgAN patients and control persons
Patients with biopsy proven IgAN were selected for entry in this study. 
Control persons in this study are persons with no underlying immunological 
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disease, who visited the ear nose throat department for a surgical nasal septum 
correction and were asked for permission for a nasal biopsy during this 
operation. Neither patients nor controls were using immunosuppressive drugs 
at the time of the study nor in the three months before biopsies were taken. No 
infections or macroscopic hematuria were present at the time of the study.
 Mean age of the patients was 51 years (range 23-71) versus 39 years 
(range 10-59) of the controls (n.s.). The male: female ratio was 78% versus 
22% in the IgAN patient group and 72% versus 28% in the control group. 
Renal function was stable in most of the patients. Mean creatinine clearance 
was 78 ml/min (range 24-136). Mean proteinuria was 1.3 gram per litre (range 
0-4.7). Neither the IgAN patients nor the control persons had an infection of 
the upper respiratory tract at the time of biopsy. 
 The study was approved by the ethical committee of the Leiden 
University Medical Centre. All individuals gave informed consent.
Nasal biopsies
One nasal biopsy was taken from each person. All biopsies were taken by the 
same investigator. Local anaesthesia was achieved by applying a cotton wool 
carrier with 50-100 mg of cocaine and 3 drops of adrenaline (1:1000) under 
the inferior turbinate, without touching the biopsy site. Biopsy specimens 
were taken from the lower edge of the inferior turbinate by using a Gerritsma 
forceps [27] and embedded in Tissue-Tek II OCT compound. The biopsies 
were immediately frozen and stored at -150 oC.
Immunohistochemical staining
Each tissue specimen was cut into 6μm-thick sections. All stainings were 
developed with the immunoalkaline phosphatase method, as previously 
described [28]. All cryosections that were accepted for evaluation had an 
undamaged basal membrane of at least 1 mm length and a surface of the 
lamina propria of at least 1 mm2. The mean length of the basal membrane was 
3.8 mm and the mean surface of the epithelial layer was 3.0 mm2. Multiple 
fi elds were counted and the number of cells is expressed as positively stained 
cells per mm2. As a negative control we replaced the primary antibody by 
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mouse IgG. Different subsets of DCs were stained using specifi c monoclonal 
antibodies. Myeloid dendritic cells were stained using mouse monoclonal 
antibodies directed to CD1a (Leu 6, Becton Dickinson, San Jose CA), anti 
DC-SIGN (CD209, DC-SIGN 1 R&D) or BDCA-1 (clone AD5-8E7; Miltenyi 
Biotec). Plasmacytoid DCs were stained with monoclonal antibodies directed 
to BDCA-2 (clone AC144; Miltenyi Biotec).
 Biopsies were coded and counted for positively stained cells, 
independently by two investigators for each antibody, as has been described 
previously [28]. Positively stained cell numbers in the epithelium and in the 
subepithelial lamina propria, 100 μm deep along the basal membrane, were 
counted, using a light microscope (Zeiss, Jena, Germany) with an eye piece 
graticulate at a magnitude of 400x and were expressed as positively stained 
cells per mm2.
Double staining
For double staining of BDCA-1 or BDCA-2 with DC-SIGN, acetone fi xed 
sections were incubated with 0.1% H2O2 and 0.1% NaN3 in PBS for 30 min 
at room temperature (RT) to block endogenous peroxidase activity. The slides 
were blocked with PBS containing 1% PBS and 5% heat inactivated normal 
human serum (NHS) for 45 minutes at RT and subsequently incubated with 
antibodies directed against BDCA-1 or BDCA-2 in PBS with 1% BSA and 
1% NHS overnight at RT. Antibody binding was detected using a HRP labeled 
goat-anti-mouse antibody (Dako, Glostrup, Denmark) in PBS with 1% BSA 
and 1% NHS for 60 min at RT. Next, the slides were blocked again with PBS 
containing 1% PBS and 5% NHS for 45 minutes followed by an overnight 
incubation with antibody against DC-SIGN in PBS with 1% BSA and 1% NHS 
at RT. The presence of DC-SIGN antibody was detected by incubation with 
a rabbit-anti-mouse IgG2b specifi c antibody (Jackson, Suffolk, UK) in PBS 
with 1% BSA and 1% NHS at RT followed by detection with a biotinylated 
goat-anti-rabbit antibody (Dako, Glostrup, Denmark) in PBS with 1% BSA 
and 1% NHS and amplifi ed with a streptavidin biotin complex containing 
alkaline phosphatase (Dako, Glostrup, Denmark). Eventually, development 
with Tyramide-FITC in tyramide buffer (NENTM Life Science Products) 
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for 30 min at RT was used to detect the presence of BDCA-1 or BDCA-2 
positive cells. For detection of DC-SIGN positive cells, Fast Red TR salt 
and naphtol tablets (both from Sigma-Aldrich, Zwijndrecht, The Netherlands) 
were dissolved according to manufacturers instructions. For development, 
equal amounts of Fast Red TR and naphtol solutions were mixed and added 
to sections for 15 minutes at RT. Slides were mounted with mowiol.
Statistical analysis
Statistical analysis was performed, using the Mann-Whitney test. The 
Spearman correlation coeffi cient was calculated to determine the correlation 
between the different subsets of DCs. P values of <0.05 were considered 
signifi cant.
Results
Demonstration of DC subsets in nasal biopsies
We collected nasal biopsies from 18 IgAN patients and 18 control persons. 
Biopsies were analysed by hematoxylin eosin (HE) staining to check the 
quality of the tissue and confi rm the presence of an epithelial layer (Figure 
1A). 
Figure 1. HE staining and negative control of nasal mucosa. Light microscopic section of nasal mucosa, 
stained with hematoxylin eosin at a magnifi cation of 100x (A). The outer epithelial layer is divided from the 
lamina propria by the basal membrane. Negative control of a biopsy stained for BDCA-1 (B).
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Figure 2. Expression of DC-SIGN, CD1a, BDCA-1 and BDCA-2 in nasal mucosa. 
Cryosections of nasal mucosa were stained for expression of DC-SIGN, CD1a, BDCA-1 
and BDCA-2 as described in material and methods. The left panel shows cryosections at an 
original magnifi cation of 100x and the right panel at a magnifi cation of 250x. CD1a positive 
cells are more frequently located in the epithelial layer. DC-SIGN positive cells and BDCA-2 
positive cell are mainly located in the lamina propria. Shown are representative pictures of 
IgAN patients.
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Cryosections were specifi cally analysed for the presence of DCs using specifi c 
monoclonal antibodies. To identify myeloid DCs, cryosections were stained for 
CD1a, DC-SIGN and BDCA-1. To quantify plasmacytoid DCs, cryosections 
were stained for BDCA-2. After staining, the number of cells was counted 
and related to the surface tissue area and compared to the negative control 
stainings (Figure 1B). 
 Positive cells are coloured red and were counted by two investigators 
independently. In all cryosections an epithelial layer, with a variable thickness 
was visible. The epithelial layer is separated from the lamina propria by the 
basal membrane. In the lamina propria, glands and vessels are visible, which 
were excluded from the analysed surface. In both the epithelial layer and 
the lamina propria DCs are present. Pictures of representative cryosections 
with an original magnifi cation of 100x (left panel) and 250x (right panel) are 
shown in fi gure 2. 
Quantifi cation of myeloid dendritic cells in nasal biopsies
Different subsets of myeloid DCs were identifi ed, using CD1a, DC-SIGN and 
BDCA-1 as markers. Biopsies were stained for BDCA-1, which is a broadly 
expressed marker for myeloid DCs. Compared to CD1a and DC-SIGN the 
absolute number of positively stained cells was highest for BDCA-1. No 
differences in BDCA-1 positively stained cells between epithelial layer and 
lamina propria were present. The number of positively stained cells did not 
differ between the control group and the IgAN patients (Figure 3). 
 The number of DC-SIGN positive cells was higher in the lamina propria 
than in the epithelial layer. Moreover the number of DC-SIGN positive cells 
in the lamina propria was signifi cantly higher in IgAN patients than in the 
control group (median 71.8 vs. 41.6 p=0.022). In contrast no signifi cant 
differences were found in the number of DC-SIGN positive cells in the 
epithelium between the two groups (Figure 3).
 In both the control group and in the IgAN patient group the number 
of CD1a positive cells was higher in the epithelial layer than in the lamina 
propria. The number of CD1a positive cells in the epithelial layer was 
signifi cantly higher in IgAN patients than in control persons (median 72.8 vs 
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20.2, p=0.009). In contrast the number of CD1a positive cells in the lamina 
propria did not differ between the IgAN patient and the control group (Figure 
3). We also looked at the actual ratio numbers of DC between the different 
compartments. No signifi cant differences in tissue distribution of positively 
stained cells was present between the two groups with respect to the different 
myeloid markers (data not shown). 
Quantifi cation of plasmacytoid dendritic cells in nasal biopsies
Plasmacytoid DCs were stained using BDCA-2 as a surface marker. The 
number of positively stained cells in the lamina propria was higher than in 
the epithelial layer. No differences were found in the number of BDCA-2 
positively stained cells between the IgAN patients and the control persons, 
neither in the epithelial layer, nor in the lamina propria (Figure 4). With respect 
to BDCA-2, no difference in actual ratio of numbers of DC between different 
sites was present between the IgAN patients and the controls. The number 
of plasmacytoid DC in these nasal biopsies was lower than the number of 
myeloid DC.
Correlations between the number of positively stained cells
To determine whether CD1a, DC-SIGN, BDCA-1 and BDCA-2 positively 
stained cells in the epithelial layer are correlated with the number of positively 
stained cells in the lamina propria, we calculated Spearman correlation 
coeffi cients. For all stainings the number of positively stained cells in the 
epithelial layer appeared to be correlated to the number positively stained 
cells in the subepithelial lamina propria. The correlation coeffi cient varied 
from 0.49 to 0.69 with p values of maximal 0.0017 (Figure 5). In both the 
control group and in the IgAN patients this correlation was found.
 We also investigated the correlation between the different subsets of 
DCs. In the epithelial layer there was a correlation between CD1a+ cells 
and BDCA-1+ cells and a correlation between DC-SIGN+ and BDCA-1+. In 
the lamina propria no correlation between CD1a and BDCA-1 was found. 
Furthermore a correlation between epithelial BDCA-1 and epithelial BDCA-2 
was present and between epithelial BDCA-1 and lamina propria BDCA-2 . 
(Table 1). 
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Figure 3. Number of different subsets of myeloid DCs in nasal mucosa of controls and 
IgAN patients. Cryosections of nasal biopsies from control persons and IgAN patients were 
stained for DC-SIGN, CD1a and BDCA-1 respectively. Positive cells in the epithelial layer 
(right panel) and in the lamina propria (left panel) were counted as described in materials and 
methods section. Bars represent median + interquartile range and the smallest and greatest 
values in the distribution. Statistics were performed using the Mann-Whitney test. p values of 
<0.05 were considered signifi cant.
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Figure 4. Number of plasmacytoid DCs in nasal mucosa of controls and IgAN patients. 
Cryosections of nasal biopsies from control persons and IgAN patients were stained for 
BDCA-2, a marker for plasmacytoid DCs. Positive cells in the epithelial layer and in the 
lamina propria were counted as described in materials and methods sections. Bars represent 
median + interquartile range and the smallest and greatest values in the distribution. Statistics 
were performed using the Mann-Whitney test.
Table 1. Correlation of different subsets of DCs in nasal mucosa. Nasal mucosa was 
stained for the presence of different subsets of DCs. Spearman correlation coeffi cients were 
determined to calculate statistical relations between the different DC molecules. p values of 
<0.05 were considered signifi cant.
DC-SIGN epithelium CD1a epithelium BDCA-1 epithelium BDCA-2 epithelium
DC-SIGN-E x n.s
DC-SIGN-LP r=0.69 *** n.s n.s. n.s.
CD1a-E n.s x
CD1a-LP n.s r=0.49 *** n.s. n.s.
BDCA-1-E r=0.50 *** r=0.39 * x
BDCA-1-LP n.s r=0.38* r=0.60 *** n.s.
BDCA-2-E n.s n.s r=0.38 * x
BDCA-2-LP n.s n.s r=0.50 ** r=0.55 ***
* p<0.05 E=epithelium
** p< 0.01 LP=Lamina Propria
*** p<0.002
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Figure 5. Correlation between DC-SIGN+, CD1a+, BDCA-1+ and BDCA-2+ cells in 
epithelial layer and lamina propria. Cryosections of nasal biopsies were stained for DC-
SIGN, CD1a, BDCA-1 and BDCA-2, as described in materials and methods section. The 
number of positively stained cells in the lamina propria and epithelial layer are plotted. 
Spearman correlation coeffi cients were determined to calculate statistical relations. Filled 
squares represent DC counts of an individual biopsie.
Double staining for DC-SIGN and BDCA-1 or BDCA-2
To further investigate the correlations between the different markers of DCs, 
we performed double stainings for DC-SIGN and BDCA-1 or BDCA-2. 
When staining for two myeloid DC markers, DC-SIGN and BDCA-1 we 
found a substantial proportion of double positive cells. However also single 
positive cells were observed (Figure 6A). When double staining for DC-SIGN 
and BDCA-2 was investigated, we found no overlap in staining (Figure 6B). 
This is compatible with the fact that these two markers are expressed on 
DC subsets proposed to be derived from different lineages (myeloid versus 
lymphoid respectively).
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Figure 6. Nasal biopsies contain DC-SIGN+ BDCA-1+ cells. Cryosections of nasal biopsies 
were stained for DC-SIGN (green) and BDCA-1 (red) (A) or BDCA-2 (red) (B) as described in 
materials and methods sections. White arrows indicate DC-SIGN+ BDCA-1+ cells. Original 
magnifi cations were x200.
Discussion
In the present study we investigated the nasal mucosa of IgAN patients for the 
presence of different subsets and numbers of DCs, as previous experiments 
suggested an aberrant immunological response in these patients. After 
mucosal vaccination with a neoantigen, the specifi c IgA immune respons 
was hampered in IgAN patients in comparison with controls, whereas no 
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differences were found in the antigen specifi c IgG and IgM responses [15]. In 
the same study no differences were found in immunoglobulin production after 
simultaneous systemic vaccination with another neoantigen Keyhole Limpet 
Hemocyanin, (KLH). Therefore we wanted to address the question whether 
IgAN patients have reduced numbers of DCs in the nasal mucosa, or have a 
different composition of specifi c subsets of DCs. To this extent, nasal biopsies 
were taken from IgAN patients and controls and were stained for the presence 
of different subsets of DCs. Our results indicate that IgAN patients did not 
have reduced numbers of DCs, and even showed higher numbers of intra-
epithelial CD1a+ cells and DC-SIGN+ cells in the lamina propria. 
 DCs as professional antigen presenting cells are present in the epithelial 
layer and form a continuous network [29]. DCs can migrate and after antigen 
uptake and processing can induce immune responses. DCs have direct effects 
on many different cells. It is well known that DC can activate naïve T cells, 
which subsequently can induce B cell responses. However also direct effects 
of DC on B cells are described, leading to isotype switching and enhanced 
immunoglobulin production [19;30;31]. These effects are dependent on 
CD40-CD40L interaction [32]. Recently it has been reported that DC can 
also induce Ig production by B cells in a CD40 independent way, through 
activation of BAFF and APRIL [33;34]. 
 In the current study we investigated the number of nasal DCs of IgAN 
patients and a control group. Our hypothesis, that the number of nasal DCs 
in the IgAN patients was lower than the number of nasal DCs in the control 
group, appeared not to be true. As a matter of fact the number of CD1a positive 
cells in the nasal epithelial layer and the number of DC-SIGN positive cells 
in the nasal lamina propria were even signifi cantly higher in the biopsies of 
the IgAN patients. This means that the formerly observed IgA hyporespons 
after nasal vaccination can not be explained by a reduced number of antigen 
presenting cells. 
 The different subsets of DCs in human are not fully functionally 
characterized and so far most knowledge about their function is from in vitro 
experiments. Dubois et al. have described an increase of IgA production via 
stimulation of naive B cells by CD34-derived interstitial DC, but no effect 
Dendritic cells in nasal biopsies of IgAN patients
72
on IgA production after stimulation with Langerhans cells which are derived 
from a CD1a positive precursor [31]. This suggests higher IgA production 
when DC-SIGN positive and BDCA-1 positive DCs are present. IgAN 
patients appeared to be hyporesponders after mucosal vaccination. Whether 
this hyporesponse is related to the higher numbers of CD1a positive DCs 
in the epithelial layer remains speculative. An alternative explanation for 
the mucosal hyporesponsiveness of IgAN patients, could be that DC are 
functioning well, but that there are defects in the B or T cells. Recently it was 
shown that CD4+ T cells of patients with IgAN show an aberrant expression 
of homing receptors, potentially contributing to altered mucosal immune 
responses [3].
 In vivo the type of DC that captures and presents an antigen to T cells 
is probably decisive whether a processed antigen gives rise to an immune 
response or is tolerated. In the pathogenesis of pulmonary diseases like asthma 
and chronic obstructive pulmonary disease DCs play a central role [36]. As 
DCs in the upper respiratory tract are in contact with many antigens each day, 
a dysfunction of this complex system might contribute to the pathogenesis of 
diseases in which the mucosa is involved, such as IgAN. The additional effect 
of local tissues on the function or phenotype of DCs in vivo is also unknown. 
It has recently been described by Allam et al. that mucosal myeloid CD1a+ 
DCs differ from their skin counterparts by the expression of the high affi nity 
receptor for immunoglobulin E [37]. 
 Recently we have studied the capacity of monocyte-derived DCs from 
IgAN patients and control persons to induce IgA production in an in vitro 
model. We found a reduced capacity of DCs from IgAN patients to increase 
IgA production by naïve B cells, when DCs were cultured in the presence 
of IL-10 and CD40L [22]. Whether the increased number of CD1a and DC-
SIGN positive DCs in the nasal biopsies of IgAN patients are a kind of 
compensation for the reduced functional capacity to increase IgA production 
is only speculative. It would be interesting to study functional activities 
of mucosal DC of IgAN patients. However techniques and availability of 
tissue are presently not suffi cient to perform proper functional analysis. An 
alternative way to get more information on DC function could be further 
phenotypic analysis of tissue DC, preferably during antigen challenge.
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In our study we found for all different stainings a strong correlation between 
the number of positively stained cells in the epithelial layer and in the lamina 
propria. We also calculated the correlation between different markers and found 
in the epithelial layer a strong correlation between CD1a+ and BDCA-1+ and 
a correlation between DC-SIGN+ and BDCA-1+ DCs. To further investigate 
this correlation we performed double staining for DC-SIGN and BDCA-1 
and showed that there were double positive cells. This result is comparable 
with an analysis of DC subsets in human kidney in which we showed that 
many cells were double positive for DC-SIGN and BDCA-1 [38]. In cell 
suspensions of human pulmonary tissue, many CD1a+ DC were also positive 
for BDCA-1 [36]. A weaker correlation was also present between BDCA-1 
and BDCA-2 in the epithelial layer. Based on these observations we conclude 
that the correlations in DC staining we observed in our nasal biopsies are 
explained partially by double staining of the same cells and partially by local 
circumstances that result in the attraction of multiple DC subsets. 
 In conclusion the number of DCs in the nasal mucosa is not reduced in 
IgAN patients. We have shown that the number of CD1a positive epithelial 
DCs and the number of DC-SIGN positive cell in the lamina propria of IgAN 
patients in nasal biopsies is even signifi cantly higher in comparison with 
control persons. Taken together with the observed IgA hyporesponse after 
mucosal vaccination with a neoantigen we therefore believe that reduced 
hyporesponsiveness of IgAN-DC may be the most probable cause for a 
mucosal hyporesponse in IgAN. 
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Summary
IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide, characterized by mesangial IgA1 deposits. We have previously 
demonstrated that IgAN patients have a hampered IgA immune respons after 
mucosal challenge with a neoantigen. Dendritic cells (DCs) are critically 
involved in the initiation of humoral immune responses, not only via activation 
of T helper cells, but also via direct effect on naïve B cells. The aim of this 
study was to investigate the capacity of DCs from IgAN patients to regulate 
IgA production. 
 DCs were generated by culturing monocytes for 7 days in the presence 
of IL-4 and GM-CSF. DCs from either IgAN patients (n=12) or controls 
(n=12) were cultured for 14 days with naïve B cells in the presence of CD40L-
transfected mouse fi broblasts (L-CD40L cells) and medium with or without 
IL-2 or IL-10. Supernatants were tested for the presence of immunoglobulins 
by specifi c ELISA. 
 In the presense of CD40L and IL-10, DCs were able to increase 
immunoglobulin production by naïve B cells. DCs of IgAN patients induced 
signifi cantly (p=0.026) less IgA production than DCs of control persons (2.30 
μg/ml vs. 5.24 μg/ml), whereas no differences were found in the IgG and IgM 
production. When DCs were replaced by supernatant of CD40L-stimulated 
DCs of patients and controls, IgA production was increased, but no difference 
was seen between the two groups. 
 In the present study we show that DCs of IgAN patients have an impaired 
capacity to induce IgA production in naïve B cells, which might explain the 
observed IgA hyporesponse upon mucosal challenge with a neoantigen.
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Introduction
IgA nephropathy (IgAN) is the most common primary glomerulonephritis 
worldwide [1-3]. Overall, IgAN is the cause of renal failure in +10% of the 
people being on chronic renal replacement therapy in Western Europe and 
the United States. Patients usually present with microscopic hematuria and 
proteinuria. In renal biopsies, IgAN is characterized by IgA1 and complement 
component 3 (C3) deposits in the mesangium of the glomeruli [4;5]. After 
kidney transplantation, recurrent IgA deposits are found in the allograft in a 
high percentage of the cases. Moreover occasional accidental transplantation 
of a kidney of an IgAN patient lead to disappearance of IgA deposits [6;7]. 
Therefore it is most likely that the major cause of IgA deposition in the 
renal mesangium lies in IgA itself or the interaction between IgA and the 
mesangium.
 The pathogenesis of IgAN is not clear. Several factors have been 
implicated to play a role in the formation of IgA immune deposits in the 
mesangium. Both quantitative and qualitative differences in IgA seem to be 
a factor involved in the pathogenesis [8;9]. Detailed biochemical analysis of 
IgA1 suggests that underglycosylated IgA1 is enriched both in serum and in 
mesangial deposits [10;11]. Moreover it has been suggested that glycosylation 
of IgA might be affected by the mode of B cell activation and the cytokine 
milieu [12].
 A clinical observation is that upper respiratory tract infections 
frequently lead to an increase of hematuria (‘synpharyngitic hematuria’) 
[13;14]. Therefore a dysregulation of the mucosal immune response of IgAN 
patients might play a role in the pathogenesis [1]. Mucosal vaccination of 
IgAN patients with neoantigens was shown to lead to an impaired mucosal 
and systemic IgA response, compared with healthy persons [15;16]. In these 
studies no differences in the antigen specifi c IgG and the IgM responses 
were measured. These results seemed in confl ict with the original idea that 
IgAN patients are hyperresponders after vaccination, as suggested by the 
higher serum IgA titers in most IgAN patients. The observation that systemic 
vaccination of IgAN patients with a recall antigen appeared to give rise to 
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a systemic and mucosal hyperresponse, might be explained by an increased 
level of immunological memory [17-19]. When we performed a simultaneous 
mucosal and systemic vaccination with a neoantigen, only the mucosal 
challenge showed a hyporesponse, whereas the systemic challenge was not 
different between patients with IgAN and controls [15]. This suggests that the 
mucosal immune regulation has specifi c regulatory features [20;21].
 Immunoglobulin production is the result of a complex interaction 
between B cells, T cells and antigen presenting cells like dendritic cells 
(DCs). Naïve B cells are IgM/IgD positive and have to undergo a program 
of affi nity maturation, isotype switch and plasma cell differentiation before 
high affi nity IgG or IgA antibodies can be produced [22]. This process is 
tightly regulated by activated T helper cells through expression of CD40L/
CD154 and the production of cytokines. In the hyper-IgM syndrome a genetic 
alteration of CD40L results in a defi cit of circulating IgG and IgA [23;24]. 
For IgA production, cytokines like IL-10 and TGF-β have been shown to 
determine the isotype specifi city [25]. More recently it has been shown in an 
in vitro model that DCs were capable to further increase IgA production in the 
presence of IL-10 and CD40L [26;27]. Therefore, DCs seem to have a direct 
effect on B cells, next to its well established role in the activation of T helper 
cells [28;29].
 In the present study we investigated the capacity of DCs from IgAN 
patients to induce IgA production in naïve B cells in vitro and compared this 
with DCs from healthy volunteers. We found that DCs from IgAN patients 
induce less IgA production, whereas no differences for IgG and IgM were 
found.
Materials and methods
Selection of IgAN patients
Biopsy proven IgAN patients were selected for entry in this study. Patients did 
not take immunosuppressive drugs within a three months period before blood 
samples were taken. Age and sex matched healthy controls were selected. 
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No infections or macroscopic hematuria were present at the time of blood 
sampling. 
 Mean age of the patients was 42 years versus 39 years of the controls 
(Table 1). The male: female ratio was 83% vs 17% in both groups. Renal 
function was preserved and stable in most of the patients. Mean creatinine 
clearance was 78 ml/min. Only one patient had a creatinine clearance lower 
than 25 ml/min. Proteinuria was mild with a mean value of 1.3 gram per litre. 
The study was approved by the Ethical Committee of the Leiden University 
Medical Centre. All individuals gave informed consent.
Table 1. Characteristics of IgAN patients and control persons
IgAN patients controls
Number 12 12
Mean age (range) 42 (22-62) 39 (30-52)
Male/female 10/2 10/2
Years since diagnosis (range) 8 (1-22)
Serum creatinine (μmol/ml) 135 (79-347) N.D
Creatinine clearance (ml/min) 78 (19-117) N.D
Proteinuria (g/L) 1.3 (0-1.9) N.D
Erythrocyturia (0-4+) 2+ N.D
N.D is not determined
Generation of dendritic cells 
Fifty ml of heparinized peripheral blood was collected from each IgAN patient 
and healthy control person. PBMC were isolated by Ficoll-Hypaque (Sigma, 
St. Louis, MO) density gradient centrifugation. Cells were washed three times, 
to remove Ficoll and thrombocytes. Subsequently monocytes were isolated 
by Percoll (Pharmacia, Uppsala, Sweden) gradient centrifugation and plastic 
adherence for 2 hours in six wells culture plates (2.5x106 cells/well; Costar, 
Cambridge, MA). Adherent monocytes were cultured for 7 days in RPMI 1640 
containing 10% heat-inactivated FCS and penicillin/streptomycin (all from 
Gibco/Life Technologies, Breda, The Netherlands), in the presence of 5 ng/ml 
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GM-CSF (Leucomax, Novartis Pharma B.V., Arnhem, The Netherlands) and 
10 ng/ml IL-4 (Peprotech, Rocky Hill, NJ) [30].
Analysis of cell surface phenotype by fl ow cytometry
Cells were harvested and washed in PBS containing 1% BSA and 1% heat-
inactivated normal human serum and 0.02% NaN3. FACS analysis was 
performed using mAb against CD1a (Leu-6) and CD14 (Leu-M3) (both Becton 
Dickinson & Co., Mountain View, CA) and CD86 (IT2.2; Pharmingen, San 
Diego) and CD209 (mouse anti-human DC-SIGN, AZN-DI, kindly provided 
by Prof. Yvette van Kooyk. Free University Medical Centre, Amsterdam, 
The Netherlands). Staining was visualized by using PE-conjugated goat-
anti-mouse Ig (Dako, Glostrup, Denmark), assessed for fl uorescence using a 
FACScan and analyzed with WinMDI software (Becton Dickinson & Co.).
Isolation of serum IgD+ (sIgD+) B lymphocytes
B cells were isolated from tonsils by the Ficoll-Rosetting method [25]. 
Purifi ed sIgD+ B lymphocytes were separated using a preparative magnetic 
cell sorter (MACS; Miltenyi Biotec GmbH, Bergisch Gladbach, Germany) 
according to the experimental procedure described in detail by Miltenyi et al. 
[31]. IgD was expressed on >99% of the sIgD+ B cell population as assessed 
by FACScan analysis (Becton Dickinson & Co.).
B cell activation
All cultures were performed in Iscove’s modifi ed Dulbecco’s medium (IMDM) 
glutamax (Gibco/Life Technologies) supplemented with 10% heat-inactivated 
FCS and ITS (Insulin 5 μg/ml, Transferrin 5 μg/ml and Selenium 5 ng/ml 
fi nal concentration; Sigma). 1x104 IgD+ B cells were cultured in the presence 
of 1x104 irradiated (33 Gy) DC and 0.25x104 irradiated (75 Gy) murine L-cell 
fi broblasts stably transfected with human CD40L (L-CD40L cells) [32] in a 
fi nal volume of 200 μl in 96-wells round bottom tissue culture plates (Costar) 
[26]. In each experiment cells were cultured in the presence of medium, IL-2 
(20 U/ml) (Chiron, Emeryville, CA), or IL-10 (50 ng/ml)(Schering Plough, 
Dardilly, France). Each culture condition was performed in 5 fold. Conditions 
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without DC and/or without B cells served as negative controls. Supernatant 
was harvested after 14 days.
Generation of supernatant from dendritic cells
5x104 DCs were cultured for 72 hrs in combination with 1x104 irradiated 
L-CD40L cells or 1x104 L-Orient cells in a total volume of 500 μl in IMDM 
glutamax supplemented with 10% heat-inactivated FCS and ITS. Supernatant 
was harvested and stored at -20ºC until further use. 
B cell experiments with supernatant of dendritic cells
All cultures were performed in IMDM glutamax supplemented with 10% heat-
inactivated FCS and ITS. 1x104 IgD+ B cells were cultured in the presence of 
50 μl supernatant of CD40L-stimulated or unstimulated DCs and 0.25x104 
irradiated (75 Gy) L-CD40L cells with or without IL-10 (50 ng/ml) in a fi nal 
volume of 200 μl in 96-wells round bottom tissue culture plates (Costar). Each 
culture condition was performed in 5 fold. Conditions without supernatant 
and/or without B cells served as negative controls. Culture supernatant was 
harvested after 14 days and tested for Ig by ELISA. 
Immunoglobulin quantifi cation
IgA, IgA1, IgA2, IgG and IgM levels were determined by specifi c sandwich 
enzyme-linked immuno assay (ELISA), as described [15]. All ELISA’s were 
performed in 96-well polystyrene plates (Greiner, Alphen a/d Rijn, The 
Netherlands). Optical density (OD) was measured at 415 nm on a microplate 
reader (Bio-Kinetics Reader EL 312e, Biotek Instruments Inc., Winooski, VT, 
USA).
IL-10 quantifi cation
IL-10 was measured by a commercially available ELISA kit (Sanquin, 
Amsterdam, The Netherlands) and was used as indicated by the 
manufacturer.
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Statistical analysis
Statistical analysis was performed, using students t-test, P values less than 
0.05 were considered signifi cant.
Results
Immunoglobulin production is dependent on the presence of CD40L and 
increased by dendritic cells
To be able to investigate the capacity of DCs of IgAN patients to modulate 
IgA production by naïve IgD+ B cells, we established a culture system based 
on the presence of L-CD40L cells, IgD+ naïve B cells and recombinant 
cytokines. Independent of the cytokines used, only very low concentrations of 
immunoglobulins were detected in the absence of CD40L. In the presence of 
CD40L the immunoglobulin production of all different isotypes was strongly 
upregulated (Figure 1). This Ig production is dependent on the presence of 
IL-10 and is not supported by IL-2. Next, monocyte-derived DCs were added 
to CD40L-activated B cell cultures. In the absence of exogenous cytokines, 
DCs did not signifi cantly stimulate Ig production. However in the presence of 
IL-10 and also in the presence of IL-2 [33] DC stimulated production of IgA, 
IgG and IgM (Figure 2). This model allows the investigation of the B cell 
stimulating capacity of DCs of patients with IgAN. 
No phenotypic differences between dendritic cells of IgAN patients and 
control persons
Immature DCs were generated by culturing monocytes from patients and 
controls in the presence of IL-4 and GM-CSF during 7 days. Monocytes 
are negative for CD1a and DC-SIGN and have high expression of CD14. 
Immature DCs have surface expression of DC-SIGN, a specifi c DC marker, 
and have high expression of CD1a and low expression of CD14 (Figure 3A). 
The phenotype of immature DC of IgAN patients and controls did not differ in 
expression of DC-SIGN (Figure 3B). Pilot experiments showed that individual 
contaminating B cells in the DC population could affect the outcome of Ig 
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production. This effect could be prevented by irradiation of (30 Gy) the DC 
population. Irradiation did not affect CD40L-induced functions of DC, like 
IL-10 production (Figure 4A) or CD86 expression (Figure 4B).
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Figure 1. Immunoglobulin production is dependent on CD40L and IL-10. Highly purifi ed 
IgD+ B cells (104) were cultured with 75 Gy irradiated non-transfected L cells (L-orient) or 
CD40L transfected L cells (L-CD40L) (0.25x104) in the presence of IL-2 (20 U/ml) or IL-10 
(50 ng/ml) as indicated. After 14 days supernatants were harvested and tested for IgA, IgG and 
IgM production using specifi c ELISA’s. Data shown are the mean +SD of quadriple cultures 
and represents one out of 3 independent experiments.
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Figure 2. DCs increase Ig production by naïve B cells. Highly purifi ed IgD+ B cells (104) 
were cultured with 75 Gy irradiated CD40L transfected L cells (0,25x104) in the absence of 
DCs (grey bars) or in the presence of DCs (104) (black bars), in the presence of IL-2 (20 U/ml) 
or IL-10 (50 ng/ml) as indicated. After 14 days supernatants were harvested and tested for IgA, 
IgG and IgM production using specifi c ELISA’s. Data shown are the mean +SD of fi vefold 
cultures and are representative of 3 independent experiments.
Co-culture of dendritic cells from IgAN patients with naïve B cells results 
in a reduced increase in IgA production
In order to compare the capability of DCs from IgAN patients with DCs from 
healthy volunteers in the induction of IgA switch in naïve B cells, monocytes 
were isolated from IgAN patients (n=12) and healthy volunteers (n=12). 
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Controls and IgAN patients were always tested in parallel with the same 
source of B cells and the same L-CD40L cells. Co-culture in the presence 
of IL-10 resulted in less IgA production induced by DCs from IgAN patients 
as compared to DCs from healthy control persons (5.34 μg/ml versus 2.34 
μg/ml; p=0.026) (Figure 5A). No difference between patients and controls 
was observed when cocultures were performed in the presence of IL-2. To 
determine the specifi city for the IgA regulation, also IgG and IgM were 
measured in the same supernatants. In all conditions, there were no differences 
between the IgAN patient group and the control persons with respect to IgG 
and IgM production (Figure 5B).
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Figure 3. Analysis of CD1a, CD14 and DC-SIGN expression on monocytes and immature 
dendritic cells from controls and patients with IgAN. (A) Surface expression of CD1a, 
CD14 and DC-SIGN on monocytes (upper panel) and monocyte derived DCs (lower panel) 
was determined using FACS analysis. Specifi c staining is represented by the fi lled histograms 
and control staining by the open histograms. Shown is a representative example of DCs from a 
control.  (B) Surface expression of DC-SIGN on DC from control persons and DC from IgAN 
patients was determined using FACS analysis. Shown are the mean fl uorescence intensity 
(MFI) +SD of 5 control persons and 5 IgAN patients. 
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Figure 4. Irradiation of DCs does not infl uence CD40L induced IL-10 production and 
CD86 expression. (A) DCs (5x104) were either irradiated (33 Gy) or not irradiated and cultured 
for 72 hours in the presence of control L cells (left panel) or CD40L-transfected L cells (104) 
(right panel). IL-10 production was measured by specifi c ELISA. Shown are the mean +SD of 
quadriple cultures. (B) Surface expression on DCs of CD86 was determined by FACS analysis. 
Shown is the mean of three experiments.
In our analysis it was clear that there was a large individual variation. Therefore 
next to the mean absolute production of IgA we calculated the production of 
IgA induced by the patient-DC as a ratio of the response induced by control-
DC in the same experiment. From this analysis it is clear that although the 
mean ratio of the 12 patients investigated is 0.43+0.32, this ranged between a 
complete defi ciency (ratio<0.05) and a normal response (ratio 1.05) (Figure 
6).
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Figure 5. DC from IgAN patients induce less net IgA production compared with controls. 
(A) Highly purifi ed IgD+ B cells (104) were cultured with 75 Gy irradiated CD40L transfected 
L cells (0.25x104) in the presence of DCs from controls (n=12) or in the presence of DCs (104) 
from patients with IgAN (n=12), in the presence of IL-2 (20 U/ml) or IL-10 (50 ng/ml) as 
indicated. After 14 days supernatants were harvested and tested for IgA. Data shown are the 
mean +SEM of fi vefold cultures of 3 independent experiments. (B) IgG and IgM production 
was measured using specifi c ELISA’s. Data shown are the mean +SD of fi ve fold cultures of 
3 independent experiments.
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Figure 6. Ratio of IgA production induced by DCs from patients relative to controls. 
Mean individual IgA production induced by DC from patients with IgAN is divided by the 
mean IgA production induced by DC from control persons and expressed as a ratio. Shown are 
the mean +SD of fi ve measurements. 
Dendritic cells from IgAN patients induce less IgA1 and IgA2 production 
than DCs from healthy control persons
Next to the measurements of total IgA, also production of IgA subclasses, 
IgA1 and IgA2 were determined. Comparable with total IgA, the addition of 
DC together with IL-2 and IL-10 to naïve B cells induced both IgA1 and IgA2 
production. In line with previous results and with the difference in serum 
concentrations of these subclasses, the production of IgA1 was much stronger. 
As observed for total IgA, DCs derived from IgAN patients induced less 
IgA1 as well as IgA2 compared to controls, which was again restricted to the 
conditions with exogenous IL-10 (Figure 7). 
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Figure 7. DCs from patients with IgAN induce less IgA1 and IgA2. Highly purifi ed IgD+ 
B cells (104) were cultured with 75 Gy irradiated CD40L transfected L cells (0.25x104) in the 
presence of DCs from control persons (grey bars) (n=12) or in the presence of DCs (104) from 
patients with IgAN (black bars) (n=12), in the presence of IL-2 (20 U/ml) or IL-10 (50 ng/ml) 
as indicated. After 14 days supernatants were harvested and tested for IgA1 (A) and IgA2 (B). 
Data shown are the mean +SD of fi vefold cultures of 3 independent experiments. 
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Figure 8. Supernatant of CD40L stimulated DCs can induce IgA switch, but to a lesser 
extent than DCs. (A) DCs (5x105) of control persons and IgAN patients were cultured in the 
presence of medium, control L-cells (unstimulated supernatant) or CD40L-transfected L-cells 
(stimulated supernatant) (105) in a total volume of 500 μl. After 72 hours supernatants were 
harvested and 50 μl of each supernatant was added to naïve B cells (104) in the presence of 
IL-10 (50 ng/ml). After 14 days supernatant was harvested and tested for IgA, using specifi c 
ELISA. (B) DCs (104) from the same control persons and IgAN patients were added to naïve 
B cells (104) in the presence of medium or IL-10 (50 ng/ml). After 14 days supernatant was 
harvested and tested for IgA, using specifi c ELISA.
Supernatant from cultured dendritic cells can induce IgA production in 
the presence of IL-10
In order to investigate whether a soluble factor, produced by DCs, is responsible 
for the differences in IgA production between the two groups, we generated 
supernatant from CD40L-stimulated DCs and from DCs cultured without 
CD40L. After 72 hours supernatant from this culture system was harvested 
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and added to naïve B cells in the presence of CD40L with or without IL-10. 
In the absence of exogenous IL-10, DC supernatant could not induce IgA 
production (data not shown). However in the presence of IL-10, especially 
supernatant of CD40L-activated DC could augment IgA production. However 
it should be noted that this effect is small compared to the effect of intact 
cells and importantly did not show a difference between controls and patients 
with IgAN (Figure 8A). In the same experiments, irradiated DCs were also 
investigated using the same B cells demonstrating again a hyporesponse of 
DC from IgAN patients (Figure 8B).
Discussion
In the present study, using an in vitro model, we show that monocyte-derived 
DCs of IgAN patients have a reduced capacity to induce IgA1 and IgA2 
production in naïve B cells compared to DCs from control persons. This 
difference was seen provided that CD40L and IL-10 were present. In contrast, 
IL-2 also increased immunoglobulin production, but in this condition there 
was no difference in the B cell stimulatory capacity of DCs derived from 
IgAN patients or controls. No differences in IgG and IgM production were 
measured, independent of the different cytokines that were used. Addition 
of supernatant from CD40L stimulated DCs to naïve B cells resulted in Ig 
production, but did not result in a difference between controls and IgAN 
patients. This suggests that a DC membrane bound factor is responsible for 
the difference.
 IgAN is a disease with a wide variety in clinical presentation and 
outcome. Some patients have a rapidly progressive renal deterioration 
leading to renal failure within a short time period, while others have stable 
kidney function for many years. Eventually about 30-40% of the patients 
will develop renal failure. It is generally accepted that genetic factors are 
involved in the pathogenesis of IgAN [34]. Not only familial cases of IgAN 
have been described, but also a linkage between locus 6q22-23 and IgAN has 
been described [35;36]. It is tempting to speculate that the variation in IgA 
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stimulatory capacity (Figure 6) might relate to some of these genetic factors. 
Alternatively, the in vitro hyporesponsiveness could potentially relate to the 
severity of IgAN. However in our study there was no correlation between 
clinical parameters like creatinine clearance or hematuria and the IgA inducing 
capacity (data not shown). 
 Vaccination studies have clearly demonstrated that patients with IgAN 
have a disturbed regulation of the mucosal immune response. Using CTB 
as a neoantigen we have previously shown that patients with IgAN show a 
specifi c IgA hyporesponsiveness, with normal IgG and IgM responses [15]. 
Importantly, simultaneous systemic administration of another neoantigen 
did not result in an IgA hyporesponse. These results indicate that the defects 
observed in IgA production are not generalized, but might be confi ned to the 
mucosal compartment. Regulation of IgA production is a complex process 
dependent on B cells, T cells and antigen presenting cells, but might also 
be affected by environmental mucosal factors. Previous in vitro studies 
investigating B cells or T cells of IgAN patients have not clearly pinpointed 
towards a molecular defect [37-39]. 
 Total IgA production depends on IgA switch by IgD+ B cells [26] and 
further proliferation and differentiation of these B cells. Class switch to IgA is 
a complex event, in which rearrangement of genes has to take place [40-42]. 
This process is dependent on the interaction between T cells and B cells and is 
infl uenced by many other factors. A key role in this process is the interaction 
between the TNF-R member, CD40 and its ligand [43]. This is demonstrated 
in the hyper-IgM syndrome in which a genetic alteration of the CD40L gene 
is responsible for low amounts of serum IgA, IgG and IgE [23;24]. Next to 
CD40L, IgA production is regulated by cytokines like IL-10 and TGF-β that 
act directly on B cells. Moreover as also shown in this study, DCs can further 
increase IgA production. Previous studies using similar IgD+ tonsillar B cells 
have demonstrated that DCs augment the isotype switch process as proven 
by the increase in switch circles [44]. Although our system did not allow a 
direct investigation of the switch process, it is likely that this contributes to 
the increased IgA production. The nature of the DC signal promoting IgA 
production is at present not known. Although there is a B cell stimulating 
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factor in the supernatant of activated DC, our experiments with supernatant 
suggest that the difference between patients and controls seems to be caused 
by a membrane factor. Recently it has been shown that signalling through 
BAFF, another member of the TNF-R family, can also augment IgA switch 
in a CD40-independent manner. However, it was shown that BAFF acted 
in concert with anti-IgM B cell activation, but not in concert with CD40 
signalling [45]. Moreover in preliminary experiments we were not able to 
show BAFF expression on normal monocyte derived DCs (data not shown). 
Therefore it is not likely that difference in BAFF expression can explain the 
observed in vitro differences in IgA production. 
 In the present study we have investigated monocyte-derived DC, 
and have tried to link the functional capacity of these cells to the observed 
mucosal hyporesponsiveness. At present it is unclear how these cells relate to 
mucosal DC populations. It will be a major technical challenge to investigate 
the functional capacities of mucosal DC directly, especially due to the 
limited access to mucosal tissues of these patients. However an intruiging 
observation in our study was that the defective IgA production, induced by 
DC, was only observed in the presence of IL-10. When DC were combined 
with IL-2, there were no functional differences between patients and controls. 
This suggests that there are at least two different mechanisms by which DC 
can increase IgA production by naive B cells. Until now there are no clues 
about the underlying molecular mechanisms. Similarly, it is not clear under 
which conditions in vivo IgA production is under the control of IL-2 or 
IL-10. Genetic inactivation of IL-10 in mice does not result in major B cell 
defects or reduced circulating Ig levels [46], whereas IL-2 defi ciency does 
show dramatic reduction of circulating Ig levels [47]. In both cases, the mice 
develop chronic mucosal infl ammation, suggesting a role in mucosal immune 
regulation [46;48]. However, it seems that expression of IL-10 is more widely 
distributed and that IL-10 has a more important role as an anti-infl ammatory 
mediator [49;50]. It would be attractive to link the differential response in 
combination with IL-2 or IL-10, with the observed selective defi ciency of 
a mucosal challenge, as discussed above [15]. Which local mucosal factors 
contributed to the earlier described IgA hyporespons after vaccination remains 
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unclear. It certainly needs further research to determine the precise role of DC 
and IL-10 in the regulation of mucosal IgA production. 
 In conclusion the current data strongly suggest that DCs of IgAN 
patients have an impaired capability to enhance IgA production. These data 
support the results from an earlier study in which mucosal vaccination was 
accompanied with an IgA hyporesponse [15]. The pathogenetic role of IgA 
hyporesponsiveness in IgAN could be that an initially inadequate clearance 
of an antigen leads to a prolonged immune reaction. This prolonged immune 
reaction could eventually lead to an increased serum IgA titer. Which molecular 
factors are responsible for the impaired IgA response and whether the impaired 
capacity to induce IgA switch is restricted to certain subsets of DCs, is still 
unknown and further studies are needed to resolve these questions.
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Summary 
IgA nephropathy (IgAN) is characterized by glomerular deposition of IgA, 
often together with complement components. This deposited IgA is mainly 
polymeric in nature. Although early studies suggested a role for local 
complement activation in the development of glomerular injury in IgAN, recent 
attention has focussed on the involvement of the lectin pathway of complement 
activation in the progression of renal disease in IgAN. Additionally, we have 
found that glomerular secretory IgA deposition may be one of the initiators 
of local complement activation in the kidney. In the present review we will 
discuss recent developments in this area and provide a model of how mucosal 
immunity and renal infl ammation may be interconnected. 
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IgA Nephropathy
IgA nephropathy (IgAN) is the most common form of primary 
glomerulonephritis worldwide. The hallmark of this disease is the deposition 
of IgA1 in the glomerular mesangium [1;2]. These deposits are thought to 
be composed mainly of high molecular weight IgA1, sometimes together 
with IgG or complement components like C3 [3]. The disease shows a broad 
spectrum of clinical presentations, leading to progressive renal failure in 
a substantial proportion of patients. It has been reported that IgA deposits 
disappear after transplantation of a kidney from an IgAN patient into a non-
IgAN patient [4]. Furthermore, after renal transplantation recurrent mesangial 
IgA deposition is observed in about 50% of patients [5]. These results strongly 
suggest that the basic abnormality of the disease lies within the IgA immune 
system rather than within the kidney. It is likely that several factors contribute 
to the development of IgAN, including the nature, glycosylation pattern and 
composition of IgA, dysregulation of the IgA immune response, and changes 
in the clearance of IgA from the circulation [6]. 
 Serum levels of IgA are increased in approximately 50% of patients 
with IgAN [7]. Importantly, in other diseases associated with increased 
serum IgA, such as IgA myeloma, mesangial IgA deposition is not seen 
suggesting there is something particular about the IgA molecule in IgAN that 
promotes mesangial deposition. One of the most consistent changes seen in 
the circulating pool of IgA is aberrant IgA1 glycosylation, possibly due to a 
reduced activity of core 1 ß1,3-galactosyltransferase (reviewed by Jan Novak 
in this issue). This aberrantly glycosylated IgA has also been demonstrated in 
glomerular IgA deposits, suggesting such molecules have a predisposition to 
mesangial deposition compared to normally glycosylated IgA [8].
 The increase in circulating IgA1 levels appears to be the result of 
an increased production of this isotype by the bone marrow [9] and a low 
clearance rate by the liver [9;10]. Mucosal pIgA plasma cell numbers are 
normal or even reduced in IgAN [11], and pIgA antibody levels in mucosal 
secretions are not increased and are sometimes lower than controls [12]. 
 Interestingly, patients with IgAN often present with macroscopic 
hematuria following upper respiratory tract infections. Mucosal infection 
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or presentation of live micro-organisms leads to excess amounts of IgA in 
the systemic compartment with the propensity to induce glomerular injury. 
Immunization studies in IgAN, using different antigens and routes of 
administration, have produced confl icting results with respect to the systemic 
IgA response [12-14]. Mucosal and systemic IgA hypo-responsiveness to 
mucosal immunization with the neoantigen cholera toxin subunit B (CTB) 
has been reported [12]. Furthermore systemic antigen [12;15;16] challenge 
results in normal or increased titers of circulating pIgA1 antibodies [15;16] 
with increased levels of IgA in mucosal secretions of IgAN patients [17].
 The fundamental result of these changes in the IgA immune system 
is a qualitative and quantitative alteration in circulating IgA. We believe 
these changes have a direct impact on the systemic clearance of IgA and the 
interaction of systemic IgA with glomerular mesangial cells. These events 
are the driving force for the local infl ammatory response. Based on recent 
developments, this review will primarily focus on the role of secretory IgA 
(SIgA) and mannose binding lectin (MBL) in the pathogenesis of IgAN.
Immunoglobulin A
Immunoglobulin A (IgA) is the most abundantly produced immunoglobulin 
isotype, and plays a critical role in protecting the host against environmental 
pathogens at mucosal surfaces [18]. In humans, IgA in the circulation 
primarily consists of monomeric IgA (mIgA), and only 10-20% of the IgA is 
dimeric or polymeric IgA (pIgA). Furthermore, IgA consists of two subclasses 
namely IgA1 and IgA2. IgA1 has ten potential O-glycosylation sites and two 
N-glycosylation sites. IgA2 has no O-glycosylation sites but has two to three 
additional N-glycosylation sites. In vitro deglycosylation of IgA leads to self-
aggregation, suggesting that underglycosylation of IgA may contribute to the 
generation of high molecular weight IgA [19]. 
 In secretions, secretory IgA (SIgA) is generated during transcytosis of 
dimeric IgA (dIgA) by epithelial cells, ultimately leading to its association 
with the extracellular part of the polymeric Ig receptor (secretory component). 
Besides the presence of SIgA in the mucosa, low levels (10 μg/ml) of SIgA 
can be detected in serum [20;21].
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Figure 1. The three complement pathways of complement activation. IgA can activate both 
the lectin pathway and the alternative pathway. For both pathways polymeric IgA is a more 
potent activator than monomeric IgA. (MAC: membrane attack complex).
Complement in IgA Nephropathy
In IgAN deposits of IgA are commonly associated with the deposition of 
complement components, most often C3, the membrane attack complex 
(C5b-9) and properdin [22;23]. Furthermore, increased levels of split products 
of activated C3 have been observed in the circulation of patients with IgAN and 
associated with increased proteinuria and hematuria, suggesting involvement 
of the alternative pathway in IgAN [24]. Indeed, in vitro as well as in vivo 
studies, have shown that polymeric IgA can directly activate the alternative 
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pathway of complement, whereas monomeric IgA is a poor activator of the 
complement system [25;26] (Figure 1). The molecular basis for this difference 
between monomeric and polymeric IgA is not clear. Recently, the lectin 
pathway of complement, with the recognition molecules MBL, H-fi colin 
and L-fi colin, has been described [27;28]. MBL is able to bind directly to 
a number of micro-organisms, via carbohydrates expressed on their surface 
[29]. Upon binding to an activator, MBL activates the complement cascade 
via the lectin pathway, which plays a critical role in the fi rst line of host 
defence against these pathogens. Furthermore, genetic polymorphisms in the 
MBL gene, resulting in low serum MBL levels and non-functional MBL, have 
a negative impact on several chronic diseases [30]. 
 Evidence is accumulating that MBL and activation of the lectin pathway 
of complement can also be unfavourable for disease progression. This has been 
suggested for rheumatoid arthritis, and also for IgAN, based on renal biopsy 
studies demonstrating the presence of excess MBL in glomeruli in IgAN 
[31-33]. Furthermore, it has been shown that MBL is able to bind polymeric 
IgA, leading to activation of the lectin pathway in vitro [34]. However, there 
is no difference in the binding of MBL to IgA from healthy subjects or patients 
with IgAN [35]. The carbohydrate recognition domain of MBL is able to bind 
in a calcium-dependent way to a number of saccharides, such as D-mannose, 
L-fucose, and N-acetylglucosamine (GlcNAc). The binding of MBL by IgA 
is likely to be through the oligomannose structures present in the N-linked 
sugars of the heavy chains of polymeric IgA however this requires further 
confi rmation [35].
 Deposition of MBL in association with IgA, as a marker for lectin pathway 
activation, has been reported in a subpopulation of IgAN patients [31;32;36], 
but these fi ndings have been questioned by others [37]. Furthermore, the 
relationship of glomerular MBL deposition with parameters of renal damage 
and complement activation via the lectin pathway is inconsistent between 
different studies. Recently our group described a renal biopsy series in 
which IgA was co-deposited with MBL in 25% of examined patients [38]. 
Furthermore, patients with MBL deposition exhibited more severe renal 
disease as compared to MBL-negative cases, suggesting an important role 
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for MBL in disease progression [38]. These results indicate that activation of 
the lectin pathway, initiated via MBL and possibly also L-fi colin, occurs in a 
subpopulation of IgAN patients, implicating MBL as a biomarker for disease 
progression in these cases [38]. There have been indications that MBL can 
be expressed by intrisic renal cells, but at present the relative contribution of 
these cells to deposited MBL is unclear. These results indicate that activation 
of the lectin pathway, initiated via MBL and possibly also L-fi colin, occurs 
in a subpopulation of IgAN patients, implicating MBL as a biomarker for 
disease progression in these cases [38].
 These fi ndings at the biopsy level emphasise the importance of further 
delineating the precise composition of IgA in mesangial deposits as ultimately 
this data will inform us about the mechanisms involved in IgA deposition 
and complement activation in IgAN. Local complement activation will result 
in cell injury and induction of an infl ammatory cascade that contributes to 
disease progression. The impact of glycosylation has been reviewed in detail 
elsewhere [39] and will not be discussed further in this review. We concentrate 
on recent fi ndings concerning the presence of SIgA in renal deposits.
Secretory IgA in IgA nephropathy
About 40% of patients with IgAN have recurrent episodes of macroscopic 
hematuria frequently preceded, one or two days earlier, by infections. Upper 
respiratory tract infections occur most frequently [40], but occasionally other 
infections have been implicated, including gastrointestinal and urinary tract 
infections. Mucosal immunization with a neo-antigen in healthy individuals 
leads not only to a localised mucosal immune response but also to an antigen-
specifi c immune response in plasma, suggesting a close relationship between 
the mucosa and bone marrow. This response is reduced after immunization of 
patients with IgAN [12]. 
 Production of secretory IgA (SIgA) is a specifi c process taking place 
at mucosal surfaces and occurs following binding of dimeric IgA (dIgA) 
to the polymeric Ig receptor (pIgR) and transcytosis of this IgA across the 
mucosal epithelium [41]. Epithelial IgA transport in the opposite direction 
has also been described, where SIgA binds selectively to microfold (M) cells 
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irrespective of their antigen-binding specifi city, followed by transport of SIgA 
across the epithelium and targeting to subepithelial dendritic cells (DC) [42]. 
In vitro it has been demonstrated that human DC can bind and endocytose 
SIgA [43]. It has been suggested that this targeting of SIgA to DC may play 
an important role in mucosal immune regulation through modulation of DC 
activation [42]. 
 Importantly, not all retrograde transport seems to be associated directly 
with DC uptake, because small amounts of SIgA can also be found in human 
serum [20;44]. Moreover, increased serum levels of SIgA have been reported 
in various diseases [45-48] indicating that SIgA may be a marker of clinical 
interest. Recently our group showed that in purifi ed serum IgA preparations 
SIgA is found in high molecular weight IgA fractions and that the relative 
concentration of SIgA is higher in patients with IgAN as compared to controls 
[35]. In serum low concentrations of SIgA were measured but there were no 
differences in SIgA concentrations between patients with IgAN and healthy 
subjects. However, there was a correlation between hematuria in patients with 
IgAN and the serum SIgA concentration [21]. There also is evidence that 
systemic clearance of SIgA may be defective in IgAN [49]. 
Glycosylation of SIgA in IgA nephropathy 
As mentioned previously, it is has been suggested that the glycosylation 
of IgA is an important pathogenic factor in IgAN. The predominance of 
IgA1 in mesangial deposits and the unusual hinge region of IgA1 with 
multiple O-linked glycosylation sites has stimulated a great deal of interest 
in changes to IgA1 glycosylation in IgAN. Indeed, both in serum but more 
importantly, also in the eluate of isolated glomeruli, a specifi c reduction of 
O-linked galactosylation has been observed [50-52]. Furthermore, with size 
fractionation of eluted proteins from kidney sections, it has been found that 
these deposits contain predominantly high molecular weight forms of IgA 
[53]. Recently, we demonstrated a 120-fold accumulation of SIgA, based on 
a comparison of the composition of serum and glomerular immunoglobulins, 
in IgA eluted from isolated glomeruli in IgAN [21]. 
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Previous studies have shown a role for glycosylation of IgA in the binding 
and activation of mesangial cells [54-57]. Stimulation of mesangial cells with 
high molecular weight IgA leads to enhanced production of chemokines and 
cytokines, including IL-6, TGF-β, TNF-α, MCP-1, IL-8 and MIF [55;58;59]. 
Interestingly, SIgA binds better to mesangial cells than serum IgA, and binding 
of SIgA results in mesangial cell synthesis and release of increased amounts 
of IL-6 [21]. At present, it is unclear which mesangial cell IgA receptor binds 
SIgA.
 The glycosylation of SIgA is different to serum IgA in several respects. 
Firstly, SIgA is a tetramolecular complex consisting of two IgA molecules, 
J chain and SC wrapped around the four α heavy chains. Modelling of SIgA 
suggests that the N-glycans of the α heavy chains can be masked by SC 
[60]. This may also result in altered exposure of the hinge region O-glycans. 
Moreover, specifi c analysis of the glycosylation of the IgA heavy chains 
present in SIgA, has demonstrated different N-glycan structures compared to 
that of serum IgA. Specifi cally, terminal GlcNAc residues are present in the 
majority of the N-glycans of SIgA [60]. The O-glycans of the hinge region of 
the α heavy chain of SIgA1 display a wide range of glycan structures, which 
for the major part are now characterized [60]. It would be very interesting to 
have precise information on the glycosylation of the α heavy chains of SIgA 
in IgAN, but at present such information is not available.
SIgA in IgAN biopsy specimens
To confi rm the presence of SIgA in glomeruli in IgAN, our group stained 
kidney biopsy specimens from patients with IgAN for SIgA deposition. In 
15% of cases positive staining for mesangial SIgA was observed [61]. In a 
separate study secretory component deposition was identifi ed in 13 out of 191 
IgAN renal biopsies, while all control biopsies were negative for secretory 
component [62]. In a Japanese study all IgAN biopsies studied were positive 
for secretory component, whereas normal kidneys were negative [63]. 
Interestingly, in this study there was an association between single nucleotide 
polymorphisms (SNPs) in the pIgR and the presence of IgAN [63]. The 
relationship between secretory component deposition and other molecules in 
The role of SIgA and complement in IgA-nephropathy
110
the glomeruli, and clinical parameters of the patients, has not been studied. 
In our study, double staining and confocal microscopy demonstrated 
remarkable co-localization of SIgA and MBL, supporting the previously 
reported strong correlation between SIgA and MBL in a subgroup of patients 
[61]. In addition, there was strong co-localization with C4d, suggesting local 
complement activation. An association between SIgA and MBL has been 
reported by other investigators [60]. Royle et al. suggested that disruption 
of the non-covalent interactions between secretory component and the IgA 
heavy chain, for instance at low pH, may lead to MBL binding and subsequent 
complement activation via the lectin pathway [60]. 
 The notion of a pathogenic role of SIgA deposition in IgAN and the 
knowledge that mucosal sites are critical for the generation of SIgA raises 
interesting questions concerning the involvement of mucosal immune 
responses in IgAN. 
The role of the tonsils in IgA nephropathy
The tonsils are located at the gateway of the respiratory and alimentary tract 
and belong to the mucosa-associated lymphoid tissue. The major function 
of the tonsils is as a fi rst line of defence against viral, bacterial and food 
antigens. In IgAN tonsillar tissue contains more IgA-secreting B cells than 
healthy subjects and this increase is matched by a parallel increase in the 
number of dimeric IgA secreting cells [64]. Tonsils from patients with IgAN 
contain more IgA-producing cells compared to controls [65], and synthesise 
IgA1 which is less sialylated than serum IgA1 [66;67], suggesting that the 
tonsils may be a source of the IgA that deposits in IgAN.
 Stimulation of the tonsils by ultra short wave has been shown to trigger 
acute changes in the urinary sediment in a subgroup of patients with IgAN but 
not patients with other renal diseases [68]. These patients had suffered more 
frequent episodes of macroscopic hematuria following upper respiratory tract 
infections and had higher levels of serum SIgA preceding tonsillar stimulation 
than those IgAN patients who did not respond to tonsillar stimulation [68].
 Although no randomised controlled trials of tonsillectomy in IgAN 
patients have been reported it has been suggested that tonsillectomy can 
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improve renal outcome in some patients [69;70]. There is some retrospective 
evidence from Japan that tonsillectomy was associated with a favourable effect 
on long term renal survival in IgAN patients supporting the notion that the 
mucosal IgA immune system may have an important role in the pathogenesis 
of IgAN [71].
Immunization studies in IgAN patients
Immunization studies examining both systemic and mucosal (oral) secondary 
immune responses in IgAN have generated confl icting results with respect to 
serum and mucosal antigen-specifi c IgA responses [15;17;72-75]. In IgAN 
mucosal immunization with CTB resulted in an impaired mucosal and systemic 
antigen-specifi c IgA response compared with healthy subjects, whereas there 
was no difference in antigen-specifi c IgA responses following simultaneous 
systemic immunization with the neoantigen Keyhole Limpet Haemocyanin 
(KLH) [12]. 
 Recently, Smith et al. described the O-glycosylation pattern of antigen-
specifi c serum IgA1 against the systemic antigen tetanus toxoid (TT) and the 
mucosal antigen Helicobacter pylori (HP) [76]. In this study higher Vicia 
Villosa (lectin recognizing the Tn-antigen) binding was observed for IgA1 
specifi c for HP as compared to TT. There were no differences between patients 
and controls. This suggests that IgA1 O-glycosylation may vary in different 
immune responses and may be determined at the site of antigen encounter. 
This also would imply that an altered balance in O-glycosylation pattern 
of IgA1 in IgAN patients could potentially be a consequence of a mucosal 
immune response rather than a generic defect in B cell O-glycosylation [76]. 
 Recently we investigated the size distribution of antigen-specifi c IgA 
in serum and nasal washes after mucosal and systemic immunization [77]. 
Nasal washes contained mainly SIgA whereas serum IgA displayed the usual 
size distribution of serum IgA, being mainly monomeric. SIgA was detectable 
in these sera, and as expected restricted to the high molecular weight IgA 
fractions. We found that the antigen-specifi c IgA was found predominantly in 
the high molecular weight fractions, irrespective of the route of administration. 
Importantly, we were also able to demonstrate low but signifi cant levels of 
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antigen specifi c SIgA in serum after intranasal vaccination, strongly suggesting 
a link between mucosal immune responses and circulating SIgA (fi gure 2).
Mucosa
Circulation
SIgA
Bone marrow
Kidney
Inflammation
Proinflammatory cytokines/ 
chemokines
IgA
Mesangial cells
Complement activation
Epithelial cells
Renal injury
Upper respiratory tract infection
Increased SIgA production
Increased IgA production
Aberrant glycosylation IgA
Circulating immune complexes
Impaired IgA clearance
Higher SIgA concentration
Mesangial IgA deposition
Initiation glomerular infiltration
Complement activation
Activation of mesangial cells
MBL
B lymphocytes
dIgA
Figure 2. A model to link mucosal immune responses with deposition of SIgA in the renal 
mesangium. In IgAN three compartments are important, the mucosa, the circulation and the 
kidney. B lymphocytes present at mucosal sites will, upon activation, produce dIgA which 
will be predominantly secreted as SIgA across mucosal epithelial surfaces. Via an unknown 
mechanism, small amounts of SIgA enter the circulation and ultimately come into contact with 
mesangial cells. At the same time, both mucosal B cells and plasma cells in the bone marrow 
are producing increasing amounts of aberrantly glycosylated IgA which enters the circulation. 
The binding of SIgA and aberrantly glycosylated IgA1 leads to mesangial cell activation. 
SIgA deposition is also associated with mesangial deposition of MBL and activation of the 
complement system, resulting in more severe glomerular injury. 
Conclusion 
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In this review we have discussed the potential role for MBL and SIgA in 
the pathogenesis of IgAN. Polymeric IgA is able to activate the alternative 
pathway but also by binding MBL activate the lectin pathway of complement. 
We also have discussed the mesangial deposition of MBL in IgAN and that 
this deposition is associated with more severe renal injury. 
 Patients with IgAN often experience macroscopic hematuria following 
upper respiratory tract infections. Although there is no obvious increase in 
serum SIgA in IgAN we have described a clear relationship between serum 
SIgA concentrations and risk of hematuria in IgAN. Moreover, compared to 
other serum immunoglobulins SIgA appears to deposit preferentially within 
glomeruli in IgAN and this is refl ected by the SIgA staining observed in 
kidney biopsies of patients with IgAN. The presence of SIgA is strongly 
associated with co-deposition of MBL and the complement activation product 
C4d. Taken together, the data presented in this review support a role for SIgA 
and MBL in the pathogenesis of IgAN in a subpopulation of patients.
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Summary
Secretory IgA (SIgA), although generated at mucosal surfaces, is also found 
in low concentrations in the circulation. Recently, SIgA was demonstrated 
in mesangial deposits of patients with IgA nephropathy (IgAN), suggesting 
a role in the pathogenesis. This fi nding is in line with the belief that high 
molecular weight (HMW) IgA is deposited in the kidney. However there is 
little information on the size distribution of antigen-specifi c IgA in circulation 
upon mucosal challenge.
 In this study we measured antigen-specifi c IgA, including SIgA, 
in serum following challenge of IgAN patients and controls via intranasal 
vaccination with a neoantigen, cholera toxin subunit B (CTB). We size 
fractionated serum and nasal washes to study the size distribution of total 
IgA, SIgA and CTB-specifi c IgA. Finally we compared the size distribution 
of antigen-specifi c IgA after mucosal immunization with the distribution upon 
systemic immunization. 
 A signifi cant induction of antigen-specifi c SIgA was detectable in serum 
of both patients with IgAN and controls after mucosal immunization with CTB. 
Independent of the route of immunization the antigen-specifi c IgA response 
was predominantly in the polymeric IgA fractions, in both groups. This in 
contrast to total IgA levels in serum that are predominantly monomeric. 
We conclude that mucosal challenge results in antigen-specifi c SIgA in the 
circulation, and that the antigen-specifi c IgA response in both IgAN patients 
and in controls, is of predominantly high molecular weight in nature. No 
differences between IgAN patients and controls were detected, suggesting 
that the size distribution of antigen-specifi c IgA in the circulation is not 
specifi cally disturbed in IgAN patients.
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Introduction
IgAN is the most common primary glomerulonephritis worldwide, leading to 
renal insuffi ciency in 30-40% of patients [1-3]. The disease is characterised 
by deposits of polymeric IgA1 in the mesangium of glomeruli [4;5]. The 
pathogenesis of IgAN is still not clear. Plasma IgA levels are elevated in 
about 50% of IgAN patients, but how this higher concentration of plasma IgA 
contributes to mesangial deposition remains unclear [4;6]. Qualitative changes 
of plasma IgA1, such as the glycosylation pattern, are likely involved in the 
pathogenesis of IgAN [7;8]. IgA isolated from IgAN patients shows more 
terminal GalNAc (Tn antigen), which could contribute to deposition of IgA in 
the mesangium. Interestingly, after renal transplantation IgA depositions may 
appear in the renal allograft, suggesting, next to renal factors, a pathogenic 
role for serum IgA [9].
 The mesangial IgA deposition in IgAN consists of IgA1, together 
with complement factor C3 and sometimes IgG. Most of the deposited IgA 
consists of HMW IgA [10-12]. The composition of HMW IgA is diverse and 
may contain dimeric IgA, SIgA and complexes of IgA and the Fcα-receptor 
(CD89) and fi bronectin [2;13]. Recently we showed that in approximately 
25% of cases, mannose binding lectin (MBL) is present in renal biopsies of 
IgAN patients. The presence of MBL was associated with more histological 
damage and more proteinuria [14]. In about 15% of IgAN cases mesangial 
SIgA is present [15;16]. The presence of SIgA in renal biopsies showed a 
strong correlation with the presence of MBL and the complement degradation 
fragment C4d. Moreover, a strong colocalization of SIgA, MBL and C4d was 
observed [15]. A potential pathogenic role of SIgA is further supported by 
higher serum levels of SIgA in IgAN patients as compared to controls and 
the observation that higher levels of SIgA are correlated with more hematuria 
[12].
 Several immunization studies have shown different results with regard 
to the specifi c serum and mucosal IgA responses in IgAN patients. Both 
hypo and hyper IgA responses have been described, dependent on the type 
of antigen and the route of administration of the antigen [17-22]. How these 
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differences in immune responses are related to the pathogenesis of IgAN is 
unknown. No data are available about antigen-specifi c SIgA in circulation 
after mucosal immunization. In addition, very little is known about the size 
distribution of IgA during primary immune responses in IgAN patients.
 Therefore, we have investigated the presence of antigen-specifi c 
SIgA in the circulation after mucosal immunization. In addition we size 
fractionated sera and nasal washes collected from an earlier vaccination 
study in IgAN patients and controls, who underwent nasal mucosal and 
subcutaneous immunization with two different neoantigens. In the fractions 
we determined, in addition to total IgA and SIgA, the titers of antigen-specifi c 
IgA. As every individual was immunized with two different neoantigens via 
two different routes we were able to study whether the route of vaccination 
infl uences the size distribution of antigen-specifi c IgA. We conclude that 
after mucosal immunization antigen-specifi c SIgA appears in the circulation 
in both the patient and control group, and that antigen-specifi c IgA in serum 
is predominantly polymeric in both patients and controls, independent of the 
route of immunization. The amount of antigen-specifi c SIgA in IgAN patients 
and in controls is similar, suggesting that additional factors are involved in 
the pathogenesis of IgAN.
Materials and methods
Human subjects and immunization protocol 
In an earlier vaccination study we investigated the primary immune response 
after simultaneous mucosal and systemic vaccination of IgAN patients and 
controls in a quantitative manner [17]. Participants were immunized with 
0.33 mg of cholera toxin subunit B (CTB) intranasally by spray, and 250 
μg of keyhole limpet haemocyanin (KLH) subcutaneously, repeated by two 
administrations of identical doses after 2 and 4 weeks, as described earlier 
[17]. None of the patients had clinical or laboratory evidence of Henoch-
Schoenlein purpura, kidney function was normal or mildly impaired (creatinine 
clearance>80 ml/min) and none of the patients used corticosteroids or any 
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other immunosuppressive drug at the time of the study or at least 3 months 
before. Mean age of the IgAN patients was 40 years (range 30-47 yr). Healthy 
volunteers were recruited as controls with a mean age of 29 years (range 
24-37 yr). The study was approved by the Ethical Committee of the Leiden 
University Medical Centre. All individuals gave informed consent.
 From 20 controls and 11 IgAN patients, pre and post immunization 
samples, taken two weeks after the second booster immunization, i.e. 42 days 
from the start of the immunization protocol, were available for the assessment 
of total SIgA and antigen-specifi c SIgA. From six IgAN patients, all males 
with biopsy proven IgAN and 6 controls (5 males) suffi cient amounts of 
material were present to perform a size separation of serum. 
Quantifi cation of IgA and antigen-specifi c IgA
Total IgA, SIgA and antigen-specifi c (S)IgA levels were determined by 
specifi c sandwich enzyme-linked immunosorbent assay (ELISA). Polystyrene 
96-well plates (Greiner, Alphen a/d Rijn, The Netherlands) were coated with 
100 μl/well of the capturing antibody, appropriately diluted in PBS. Total 
IgA was detected by heavy chain specifi c, affi nity purifi ed goat F(ab’)2 
fragments against IgA (Jackson, West Grove, PA). SIgA was detected using 
a monoclonal antibody specifi c for secretory component (NI194-4; 3F8) as 
capturing antibody in a concentration of 2 μg/ml. 
 In the antigen-specifi c ELISA, plates were coated with 100 μl of CTB 
(2.5 μg/ml) (Sigma, St Louis, MO) or KLH (10 μg/ml) (Calbiochem, La 
Jolla, CA). Subsequently the plates were washed with PBS/0.05% Tween 
(PBST). Plates were incubated with appropriate dilutions of samples from 
IgAN patients and controls in PBS/1% BSA/0.05% Tween for 2 hours. 
Bound IgA was detected using mouse anti-human IgA (4E8) conjugated to 
biotin, followed by incubation with streptavidin conjugated to horseradish 
peroxidase (Zymed, Sanbio BV, Uden, The Netherlands). CTB-specifi c SIgA 
was detected by polyclonal sheep anti-human secretory component (5 μg/ml) 
(Nordic, Tilburg, The Netherlands), followed by rabbit anti-sheep conjugated 
to horseradish peroxidase (10 μg/ml) (Nordic). Enzyme activity of HRP was 
developed using ABTS (Sigma). Between each step the wells were washed 
three times with PBST. 
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Size fractionation of IgA
Serum and nasal washes, containing antigen-specifi c IgA, were size-separated 
with a HiLoadTM 16/60 HR200 Superdex prep grade gel fi ltration column (120 
ml, Amersham Pharmacia, Roosendaal, The Netherlands), run in Veronal-
buffered saline containing 2mM EDTA. Fractions were assessed for the 
presence of IgA, SIgA, antigen-specifi c IgA and total protein. 
 Percentages mIgA and pIgA in serum for each individual, were 
determined as follows: fractions containing pIgA (44-51 ml) or mIgA (52-60 
ml) were pooled and assessed for total IgA and for antigen-specifi city towards 
CTB and KLH. The percentages pIgA and mIgA were calculated by dividing 
the amount of pIgA by the sum of pIgA and mIgA together. 
Statistical analysis
Statistical analysis was performed by the Student’s T-test. Differences were 
considered signifi cant when p values were less than 0.05.
Results
Antigen-specifi c Secretory IgA in serum
Using specifi c ELISA we tested pre and post immunization serum fractions of 
controls and IgAN patients for the presence of total SIgA. The mean +SEM 
of total SIgA concentrations in serum of the control group was 18+5.6 μg/ml 
before and 22.0+6.2 μg/ml after immunization (n.s.) (Figure 1A). In the IgAN 
group pre-immunization SIgA concentration was 23.3+8.6 μg/ml and post 
immunization 20.7+6.2 μg/ml (n.s.). Comparison of the SIgA concentration 
of the controls and patients revealed no signifi cant difference, neither before, 
nor after immunization. For each individual there was a very high correlation 
between the total SIgA concentration before and after immunization (Control 
group r=0.92, p<0.0001, IgAN group r=0.99, p<0.0001), suggesting that SIgA 
levels are stable over time.
 Next, we measured SIgA specifi c for CTB in serum before and after 
immunization. In both the control group and the patient group we were able 
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to detect a small, but signifi cant increase in SIgA anti CTB after the second 
booster (p<0.001). The amount of CTB-specifi c SIgA was not signifi cantly 
different between controls and IgAN patients (Figure 1B). In these samples 
we were not able to detect secretory IgM (data not shown). As a control, sera 
of non-immunized persons were tested for the presence of antigen-specifi c 
SIgA. These sera were negative for antigen-specifi c SIgA (data not shown).
Secretory IgA in nasal washes and serum
As the antigen-specifi c total IgA response in serum was strong [17] and there 
was only a slight increase in serum for antigen-specifi c SIgA, we were interested 
in the size distribution of the antigen-specifi c IgA. We size fractionated nasal 
washes and sera to test for total IgA and SIgA concentrations. In nasal wash 
only one peak of total IgA was found, exactly overlapping the SIgA peak, 
suggesting that most, if not all, IgA in nasal washes is SIgA (Figure 2A). In 
serum the profi le of total IgA showed two distinct peaks, corresponding with 
polymeric IgA (pIgA) (44-51 ml) and monomeric IgA (mIgA) (52-60 ml) 
(Figure 2B). A high percentage of total IgA in circulation was monomeric, 
in accordance with previous observations. Secretory IgA was found in the 
polymeric IgA fractions. 
Antigen-specifi c IgA in serum after mucosal immunization consists 
mainly of polymeric IgA
To determine the size of antigen-specifi c IgA, sera of 12 immunized persons 
(6 controls and 6 IgAN patients) were size fractionated as described in the 
methods section. Fractions were measured for total IgA, antigen-specifi c IgA 
and total protein. CTB-specifi c IgA concentrations were determined in the 
fractions, relative to an internal standard and expressed as arbitrary units. IgA 
anti-CTB was present in both pIgA and mIgA fractions, with higher levels 
in the polymeric IgA fractions (Figure 3A). The percentage pIgA anti-CTB 
was 57±21 in the control group and 63±24 in the IgAN patients (n.s) (Figure 
3B). For total IgA the percentage pIgA was lower than the antigen-specifi c 
IgA in both the patient and the control group. The mean percentage pIgA of 
total IgA, was 33±2.9 in the control group and 32±3.6 in the IgAN group (n.s) 
(Figure 3C). 
Antigen-specifi c IgA response in IgAN patients
126
pre post pre post
0
5
10
15
20
25
30
35
Controls IgAN patients
Controls IgAN patients
SI
gA
 (
μg
/m
l)
A
B
Antigen-specific SIgA in serum
0
100
200
300
∆ 
O
D
 4
15
 n
m
Total SIgA in serum
Figure 1. Total SIgA and CTB-specifi c SIgA in serum of controls and IgAN patients. Pre 
and post immunization sera of controls and IgAN patients were tested for total SIgA by ELISA 
(Figure 1A). CTB-specifi c SIgA was measured before and after immunization, and expressed 
by increase in OD x 1000. Shown are individual increases in OD values of 20 controls and 11 
IgAN patients (Figure1B).
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Figure 2. SIgA is present mainly in the high molecular weight fractions of IgA. IgA of 
nasal wash and serum was size fractionated with a HiLoadTM 16/60 HR200 Superdex prep 
grade gelfi ltration column. Total IgA and SIgA was determined by specifi c ELISA. In nasal 
wash the total IgA peak and SIgA peak overlap (Figure 2A) In serum total IgA exists mainly 
of monomeric IgA and to a lesser extend of polymeric IgA. SIgA is present in the high MW 
fractions of IgA (Figure 2B). Shown are representative profi les of an IgAN patient.
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Figure 3. Percentage of pIgA and mIgA total IgA and CTB-specifi c IgA. IgA of serum was 
size fractionated with a HiLoadTM 16/60 HR200 Superdex prep grade gelfi ltration column. 
Total IgA and CTB-specifi c IgA were determined by ELISA. Figure 3A shows a serum 
profi le of total IgA and CTB-specifi c IgA of a representative IgAN patient. Concentrations of 
high molecular weight IgA (pIgA) and of low molecular weight IgA (mIgA) in serum were 
determined by ELISA for total and CTB-specifi c IgA. Figure 3B shows the percentages of 
CTB-specifi c mIgA and pIgA of 6 controls and 6 IgAN patients. In Figure 3C percentages total 
mIgA and pIgA are depicted of 6 controls and 6 IgAN patients. 
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Figure 4. Antigen-specifi c IgA after systemic immunization consists almost exclusively of 
pIgA. IgA of serum was size fractionated with a HiLoadTM 16/60 HR200 Superdex prep grade 
gelfi ltration column. Total IgA and KLH-specifi c IgA were determined by ELISA. Figure 4A 
shows a serum profi le of an IgAN patient for KLH-specifi c IgA (black line) and for total IgA 
(dotted line). Concentrations of high molecular weight IgA (pIgA) and of low molecular weight 
IgA (mIgA) in serum were determined by ELISA for total and KLH-specifi c IgA. Figure 4B 
shows the percentages KLH-specifi c mIgA and pIgA of 6 controls and 6 IgAN patients. 
Size distribution of antigen-specifi c IgA in serum after systemic
immunization
To compare the size distribution of antigen-specifi c IgA after a mucosal 
challenge with a systemic immunization, fractions were also analyzed for the 
presence of IgA anti-KLH antibodies. In all samples (6 IgAN patients and 6 
controls) IgA anti-KLH was detectable. IgA anti-KLH is almost exclusively 
present in the polymeric fractions (Figure 4A). The percentage pIgA anti-KLH 
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was 83±5.7 in the controls and 88±4.9 in the IgAN patients (n.s) (Figure 4B). 
In both groups the percentage pIgA was signifi cantly higher after systemic 
vaccination as compared to mucosal vaccination. 
Discussion
This is the fi rst study showing induction of antigen-specifi c SIgA in serum, 
upon mucosal immunization. Besides this is the fi rst study that compares the 
size distribution of antigen-specifi c IgA in serum following different routes 
of immunization. We demonstrate that the antigen-specifi c IgA response is 
mainly polymeric and independent of the route of immunization. The size 
distribution of antigen-specifi c IgA in patients with IgAN is not different from 
controls.
 SIgA might play an important role in the pathogenesis of IgAN. This 
view is supported by the fact that higher concentrations of SIgA are present in 
serum of IgAN patients and by an association of higher SIgA concentrations 
with more pronounced hematuria [12]. Another argument for the involvement 
of SIgA in the pathogenesis of IgAN comes from the observation that in 
renal biopsies of IgAN patients in about 15% of cases SIgA can be detected 
[15;16;23]. The presence of SIgA is correlated with deposition of MBL and 
C4d. It has been described that renal injury is worse in patients with MBL 
deposition [14] Recently we showed that high concentrations of SIgA were 
present in IgA eluted from a removed allograft of an IgAN patient [15;16]. 
An additional argument suggesting a pathogenic role of SIgA in IgAN, is that 
about 40% of patients show a sudden increase in hematuria [24], within two 
days after an upper respiratory tract infection. It is tempting to speculate that 
this so called synpharyngitic hematuria is mediated by SIgA produced during 
a mucosal infection
 In the present study we were able to show antigen-specifi c SIgA in 
plasma. As SIgA in serum is present in low concentrations we expected to 
fi nd only very low concentrations of antigen-specifi c SIgA. The increase in 
antigen-specifi c SIgA was small but highly signifi cant in both IgAN patients 
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and controls. SIgA is present in sera of humans in low concentration. The 
mechanism by which SIgA, produced at mucosal surfaces is transported to 
the circulation is not clear. This could be by leakage of SIgA or by active 
transport through the epithelial layer [25]. Whether SIgA in serum has a role 
in the immunological response is also a matter of debate. In our study all 
persons had low concentrations of antigen-specifi c SIgA in their serum. We 
recently showed that SIgA is present in renal biopsies of a small group of 
IgAN patients [15]. It would be very interesting to correlate the SIgA immune 
response with the absence or presence of SIgA in the biopsy. Unfortunately, 
this material is at present not available. Similarly, it has been shown that the 
glycosylation pattern of SIgA differs from serum IgA in several ways [26]. 
Whether the glycosylation patterns of (antigen-specifi c) SIgA differ between 
IgAN patients and controls and whether this infl uences deposition is at present 
not known and would require the design of a new vaccination study.
 It has long been recognized that deposited IgA in IgAN mostly consists 
of HMW IgA1 [10;11] Recently it has been demonstrated that HMW IgA has 
specifi c effector activities including MBL pathway activation of complement 
[14]. Therefore we have analyzed the size distribution of antigen-specifi c IgA 
upon simultaneous vaccination with two different neoantigens and show that 
the antigen-specifi c IgA response in both patients and controls is predominantly 
in the HMW fractions. Several immunization studies with different antigens 
and various routes of administration showed that IgAN patients have aberrant 
immune responses compared with control persons [18;19;22]. However there 
is only limited information about the size distribution of these specifi c IgA 
responses. After intramuscular vaccination with inactivated infl uenza virus, 
no differences in size distribution of antigen-specifi c IgA was found between 
IgAN patients and controls [19]. In the present study it appeared that mucosally 
administered CTB induced a clear mucosal and systemic immune response as 
described earlier [17]. Measuring the antigen-specifi c IgA response revealed 
that mucosally administered CTB induced an antigen-specifi c pIgA response 
and also to a lesser extent an antigen-specifi c mIgA response in serum. The 
antigen-specifi c IgA anti-KLH consists almost exclusively of polymeric IgA 
and a smaller fraction of monomeric IgA. Both IgAN patients and controls 
showed a similar capacity to induce these HMW responses. 
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In several immunization studies it appeared that most of the antigen-specifi c 
IgA was of the IgA1 subclass [17-19]. Although two studies showed higher 
IgA1:IgA2 ratios in IgAN patients [18;19] this fi nding was not shown in 
other studies [17;22]. It is important to realize that both the place of antigen 
presentation as well as the antigens used are of importance with respect of the 
subclass distribution. Overall there is a tendency of higher IgA1 :IgA2 ratio 
in IgAN patients after immunization. In the current study we were not able to 
differentiate between antigen-specifi c SIgA1 and SIgA2. 
 Here we describe for the fi rst time the size distribution of antigen-specifi c 
IgA after simultaneously performed mucosal and systemic immunization with 
two different neoantigens. With regard to IgAN patients, size distribution of 
IgA after systemic recall immunizations has been described. Intramuscular 
vaccination with infl uenza virus showed higher monomeric IgA titers than 
that of polymeric IgA [19]. Systemic immunization with tetanus toxoid also 
showed predominantly monomeric IgA, but higher levels of polymeric IgA 
in IgAN patients than in control persons [21]. Whether these differences in 
size of antigen-specifi c IgA are determined by the type of antigen used in 
the different studies, or by differences between primary or recall immune 
responses is not clear. 
 In conclusion, in the present study we have investigated the size 
distribution of antigen-specifi c IgA responses upon mucosal and systemic 
immunization with a neoantigen. We observed that antigen-specifi c IgA 
responses were predominantly present in HMW IgA fractions, including 
antigen-specifi c SIgA. In view of the proposed pathogenic role of HMW IgA 
in IgAN, a more detailed analysis of antigen-specifi c IgA might be required 
to characterize the altered IgA response in patients with IgA nephropathy.
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The pathogenesis of IgA nephropathy (IgAN) is still not clear, but it is now 
well accepted that an aberrant glycosylation pattern of IgA is involved. This 
is supported by the fact that in IgAN mesangial deposits of IgA contain 
high concentrations of abnormally O-glycosylated IgA1, characterized by 
undergalactosylation. In the current issue Buck et al. [1] investigated whether 
this aberrant glycosylation pattern of IgA in IgAN patients is due to diminished 
activity or reduced gene expression of specifi c glycosyltransferases. They 
investigated the activity of the enzyme β-galactosyltransferase (C1Gal-T1) and 
its molecular chaperone (Cosmc) in purifi ed B cells isolated from peripheral 
blood (PB) and bone marrow (BM) of IgAN patients and controls. They also 
measured gene expression in PB and BM cells and related this to the enzyme 
GalNAc-T2, which synthesizes the core O-glycan. Using this approach, no 
differences in O-galactosylation activity between IgAN patients and controls 
could be detected.
IgAN is a heterogeneous disease with a wide range in clinical presentations, 
varying from a-symptomatic microscopic hematuria to gross macroscopic 
hematuria and can have a variable clinical outcome ranging from normal 
glomerular fi ltration rate to end stage renal disease in up to 30% of cases. The 
histological hallmark of the disease is the presence of mesangial deposition 
of polymeric IgA1, in combination with complement factor C3 and often 
IgG or IgM. In IgAN patients the serum concentration of IgA is frequently 
increased compared with that in controls, but in addition IgA present in the 
circulation was shown to be abnormally O-glycosylated. Importantly, this 
undergalactosylated form of the IgA1 hinge region was also over-represented 
in biopsies of patients with IgAN [2]. Therefore, it is likely that this 
abnormally glycosylated IgA is involved in the pathogenesis of IgAN. The 
reduced galactosylation leads to increased exposure of the internal GalNAc 
(Tn antigen) that can be detected with specifi c lectins. Recently it has been 
suggested to use this specifi c characteristic for the development of an ELISA-
based diagnostic test in IgAN [3]. This abnormal glycosylated IgA has a 
higher tendency to self-aggregate and form complexes with IgG antibodies 
directed against epitopes in the hinge region of IgA1. Besides, in patients with 
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Henoch-Schönlein purpura, a disease closely related to IgAN with a similar 
renal histological pattern, only those patients who had abnormal glycosylated 
IgA had renal involvement, whereas patients with normal glycosylated IgA 
did not have renal involvement [4]. 
Despite the importance of aberrantly glycosylated IgA in IgAN, the 
molecular mechanisms underlying these differences are not known. With 
the identifi cation and characterization of the enzyme system responsible for 
O-linked glycosylation, including C1Gal-T1 and its molecular chaperone 
Cosmc, novel avenues of research have opened up. However, an important 
and intriguing observation is the fact that aberrant O-glycosylation seems 
to be absent in other serum proteins, whereas even for IgA it is generally 
accepted that only a small proportion of the IgA molecules show these 
alterations (Figure 1). For instance, GalNac specifi c lectins specifi cally react 
with high molecular weight fractions of serum IgA, which only constitute 
10% of circulating IgA [5].
 Since IgA1 glycosylation is determined within B lymphocytes, and 
only a fraction of the IgA1 seems to be affected, this suggest that alterations 
in glycosylation are only present in a subset of B cells. In humans, besides 
IgA the only other immunoglobulin that is O-glycosylated is IgD. Smith et 
al. have studied the glycosylation patterns of IgA1 and IgD in IgAN patients 
and in controls and observed that the abnormal underglycosylated pattern of 
IgA1 was not present in IgD [6]. As IgD is a marker of naïve B cells, this 
might suggest that defi ciencies are restricted to certain differentiation stages 
of B cells. In the study of Buck et al. [1], enzyme activities were determined 
in purifi ed B cells isolated by positive selection using anti-CD19 coated 
magnetic beads. As plasma cells are CD19 negative, this analysis might 
exclude the contribution of plasma cells. Although the number of plasma cells 
in the circulation will be low, in BM their number is expected to be higher. It 
is thought that IgA present in the circulation is produced mainly by plasma 
cells derived from the BM, suggesting that the absence of plasma cells in the 
analysis could be of importance. 
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Glycosylation deficiencies
Intrinsic in 
all cells
Intrinsic in 
all B cells
Intrinsic in 
some B cells
Regulated in 
some B cells
Undergalactosylated IgA1 in
serum and biopsies of patients 
with IgAN
GalNac–T2
C1Gal–T1 + Cosmc
B cells
α1,3
IgA1 hinge
Ser/Thr
β1,3
Altered glycosylation present 
in a minority of IgA molecules
and specific for IgA
Figure 1. Schematic view on potential mechanisms leading to aberrantly glycosylated IgA. 
Undergalactosylated IgA1 is present in serum and biopsies of patients with IgAN. This glycosylation 
is controlled during the synthesis of IgA in B cells by the glycosyltranferases C1Gal-T1 and its 
molecular chaperone Cosmc and GalNAc-T2. As other proteins seem not to be affected and only 
some of the B cells in IgAN produce undergalactosylated IgA, generalized intrinsic defects in 
B cells or other cells can be excluded. Therefore, it is postulated that either the glycosylation is 
disturbed intrinsically in some B cells, or regulatory processes affect only some B cells during an 
ongoing immune response. In the latter case, environmental or cellular signals involved in B cell 
activation and IgA production might be involved.
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The fact that the proposed defi ciencies are only present in a subset of B cells 
(Figure 1), might suggest that genetic factors are not likely to be involved. 
Nevertheless, it was recently shown that polymorphisms in the gene for 
C1Gal-T1 were associated with susceptibility for the development of IgAN in 
a Chinese population [7]. A disease in which aberrant glycosylation patterns 
are present due to genetically determined factors is the so called Tn syndrome. 
This is a rare autoimmune disorder in which a somatic mutation in the Cosmc 
gene leads to incompletely glycosylated proteins in subpopulations of all cell 
lineages [8]. It is unclear whether such a mosaic pattern can contribute to the 
aberrant glycosylation in IgAN and so far no correlation between IgAN and 
the Tn syndrome has been described.
 IgA present in the circulation is derived not only from the BM, but also 
from mucosal tissues. Interestingly, most IgA produced at the mucosa will 
be dimeric in nature, and can either be transported over epithelial barriers to 
generate secretory IgA (SIgA), or contributes to the high-MW IgA fraction in 
the circulation. Therefore, both high-MW IgA and SIgA, which can also be 
present in the circulation and in renal deposits [9], might represent a recent 
mucosal challenge. Buck et al. [1] investigated the activity of C1Gal-T1 and 
Cosmc and GalNAc-T2 in PB and BM samples taken from IgAN persons 
who had no macroscopic hematuria or intercurrent illness at the time of 
sampling. This suggests that no active immune reaction was present at the 
time of investigation, which might have masked a difference in glycosylation 
activity. 
 In a recent vaccination study, a direct comparison of glycosylation has 
been made of IgA directed against a mucosal antigen, Helicobacter pylori 
(HP), and against a systemic adjusted antigen, tetanus toxoid (TT) [10]. Both 
in IgAN patients and in controls the IgA1 against HP showed higher lectin 
binding, refl ecting more undergalactosylated IgA than the IgA against TT. 
This strongly suggests that an aberrant glycosylation pattern in IgAN could 
not only be the result of an intrinsic defect in glycosylation mechanisms, but 
also might refl ect differences in regulation of glycosylation (Figure 1). As 
immunoglobulin production is the result of a complex process, involving 
B cells, T cells, antigen presenting cells and local and systemic factors like 
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cytokines, each of these factors can potentially infl uence the glycosylation 
profi le. Dendritic cells (DC) are professional antigen presenting cells 
which have direct effects on B cells, and under the infl uence of the mucosal 
environment can promote the generation of IgA producing cells [11]. We have 
shown a reduced capacity of DC of IgAN patients to induce IgA switch [12]. 
Whether the abnormal DC function also affects the glycosylation pattern in 
IgAN patients is so far unknown.
 In conclusion it is clear that aberrantly glycosylated IgA plays an 
important role in the pathogenesis of IgAN. Glycosylation is a complex 
process, infl uenced by many factors, that can either be intrinsic or can differ 
in time and change due to locally determined circumstances. The study of 
Buck et al. [1] shows that overall there is no difference between IgAN patients 
and controls in C1Gal-T1 and Cosmc activity nor in gene expression, related 
to GalNAc-T2. Although this study’s results might appear to be negative, 
it clearly brings IgAN research at a next level. It is conceivable that more 
detailed molecular analysis will be required to unravel the mechanisms 
contributing to undergalactosylation of IgA1. This should probably include 
developments in the direction of single cell analysis of IgA producing B cells 
or longitudinal analysis of actively developing IgA immune responses upon 
mucosal or systemic challenges. 
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Primary IgA Nephropathy (IgAN) was fi rst described by Berger and Hinglais 
in 1968 [1]. Nowadays IgAN is recognized as the most common primary 
glomerulonephritis worldwide [2;3]. Initially IgAN was thought to be 
a disease with a benign character, but later it appeared that up to 35% of 
patients eventually develop end stage renal failure. In western Europe and the 
United States of America about 10% of patients undergoing renal replacement 
therapy have IgAN as underlying disease. So the impact of IgAN on individual 
patients and more general on healthcare systems is signifi cant. 
 Fourty years after the fi rst description by Berger, the pathogenesis of 
this disease is still not resolved. Generally patients develop IgAN in their 
early twenties, however it may also become obvious later in life. Men are 
more often affected than women with a ratio of 2:1. It is important to realize 
that most persons present with microscopic hematuria, without further signs 
or symptoms. About 40% of patients have macroscopic hematuria, sometimes 
starting shortly after an upper respiratory tract infection. Unfavourable 
clinical outcome is associated with high levels of proteinuria and uncontrolled 
hypertension. Furthermore a decreased glomerular fi ltration rate (GFR), at the 
time the diagnosis IgAN is made, correlates with bad outcome [4]. The only 
way to confi rm the diagnosis IgAN, is to perform a renal biopsy. Differences 
in incidence rates suggest that next to environmental factors, like viral 
infections, genetic factors are involved in the pathogenesis [5]. Although no 
exact information about incidence of IgAN is known, the prevalence of IgAN 
seems to be higher in certain countries, such as Japan, Australia and southern 
Europe. In the United Kingdom, United States and Canada the prevalence 
rates are lower [4]. It is important to realise that these incidence numbers are 
infl uenced by variance in referral rates and kidney biopsy criteria. Autopsy 
studies from Japanese unselected persons show a prevalence of mesangial IgA 
depositions of about 16% , whereas in autopsy series of unselected German 
persons the prevalence was about 5%. [6;7]. 
 So far no reliable diagnostic test, other than a renal biopsy, is available 
to predict the presence of IgAN. The disease is characterized by depositions 
of IgA, mainly IgA1, together with complement factor C3 and sometimes IgG 
in the renal mesangium [3;8]. Recurrence of IgAN after renal transplantation 
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is frequently observed, whereas on the other hand it has incidentally been 
described that IgA depositions disappear from a kidney of an IgAN patient 
when it was transplanted to a non-IgAN patient [9;10]. These observations 
contribute to the idea that the so far unresolved pathogenesis of IgAN involves 
the immune system rather than specifi c renal factors. 
 Next to immunological factors, genetic factors are likely to be involved 
in the pathogenesis of IgAN. Racial differences in susceptability to IgAN 
are observed, for instance the incidence of IgAN among African Americans 
is lower in comparison with Caucasians [11;12]. The strongest argument 
that genetic factors play a role in the pathogenesis of IgAN is that familial 
clustering of IgAN has been described [13-17]. Genome-wide linkage analysis 
of 30 families with IgAN, 24 from Italy and 6 from the United States, showed 
a close association of IgAN to chromosome 6q22-23 [18]. This locus has been 
named IGAN1. Whether this locus is involved only in familial IgAN or also 
in the isolated form of IgAN is not clear. Recently two other candidate loci, 
4q26-31 and 17q12-22, have been identifi ed as suggestive to be linked to IgAN 
in 22 Italian families with IgAN [19]. So far no specifi c genes in these loci 
infl uencing the pathogenesis of IgAN have been identifi ed. Although Schena 
et al. reported a poorer prognosis of familial IgAN, no clinical parameters are 
recognized that distinguish sporadic IgAN from familial IgAN [15].
 The variability of IgAN, in clinical presentation and outcome and in 
the histological picture of the renal biopsies, might refl ect the variability in 
genetic background or genetic factors involved in the pathogenesis of the 
disease. On the other hand differences in environmental factors or geographical 
factors might be involved in the onset of IgAN or might infl uence the clinical 
outcome and could be responsible for the wide variability of IgAN.
 Recently we identifi ed a homozygous twin with biopsy proven IgAN, 
both presenting with microscopic hematuria in combination with hypertension. 
Interestingly both patients participated in the study described in chapter 4 and 
both appeared to have DC that induced only very little IgA production by 
naïve B cells. So far homozygous twins with IgAN have not been described. 
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In the past 4 decades several abnormalities in the immune system of IgAN 
patients have been described. Both quantitative and qualitative aspects of 
IgA seem to differ in IgAN patients in comparison with controls. Overall the 
serum IgA titer is increased in 50% of patients as compared to controls [20]. 
However, other diseases with higher IgA levels in the circulation, like multiple 
myeloma or HIV infection, are not associated with depositions of IgA in the 
kidney. Several immunization studies have shown aberrant immune responses 
in IgAN patients [21-23]. Next to this, several qualitative aspects of IgA seem 
to be different in IgAN patients. The most constantly described abnormality 
concerns the disturbed glycosylation pattern of IgA in IgAN patients [24;25]. 
In IgAN patients there is a reduction of galactosyl residues in the hinge region 
of serum IgA1 [26]. The exact mechanism how the glycosylation of IgA is 
disturbed, is so far not known. Recently several glycosyltransferases have 
been described, but no differences in enzyme activity, nor in gene expression 
are present in IgAN patients.
 Chapter one as a general introduction outlines the clinical features of 
IgAN. Further, the human IgA system is described and the different structural 
aspects of IgA are discussed. It is important to realize that the human IgA 
system is unique and contains both IgA1 and IgA2, both existing in monomeric 
and polymeric forms. For this reason it is diffi cult to develop a representative 
animal model for IgAN. There are two compartments, namely the mucosal and 
the systemic compartment, where IgA is produced. The mucosal compartment 
seems to be the most important one. At mucosal sites throughout the body, 
IgA is produced in large quantities and is secreted as secretory IgA (SIgA). 
SIgA exists of dimeric IgA bound to secretory component and is involved 
in mucosal defence against viral and bacterial pathogens. Small amounts of 
SIgA however are present in the circulation. So far it is not clear what the 
physiological role of SIgA in the circulation is. In IgAN in about 15% of cases 
SIgA is present in the renal biopsies [27]. The presence of SIgA correlates 
with the presence of mannose binding lectin (MBL), suggesting that SIgA 
is involved in infl ammation in the kidney [28]. Next to mucosally produced 
IgA, IgA is produced in the systemic compartment, in the bone marrow by 
plasma cells. The role of IgA in the circulation is less clear.
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To investigate the immune response in IgAN over the years several 
immunization studies, using different antigens and different routes of antigen 
administration have have been performed. These studies have shown different 
results with respect to the IgA response in IgAN patients [21;23;29-32]. 
 Chapter two concerns a study in which the IgA response in IgAN patients 
upon simultaneous stimulation with two different antigens, administered via 
two different routes is investigated. IgAN patients and controls were immunized 
with cholera toxin subunit B (CTB) applied at the nasal mucosa and with 
keyhole limpet hemocyanin (KLH) which was administered subcutaneously. 
Both CTB and KLH are considered as neoantigens and induce a primary 
immune response. In this study we also performed bone marrow biopsies. We 
were able to detect CTB-specifi c immunoglobulin producing cells in the bone 
marrow, providing evidence for the so called mucosa-bone marrow axis. This 
further supports the idea that the two compartments, mucosal and systemic, in 
which IgA is produced are immunologically connected. 
 It appeared that after mucosal immunization IgAN patients had a 
signifi cantly, lower IgA response both at the nasal mucosa, as well as in 
serum. Besides the number of CTB-specifi c IgA producing cells in the bone 
marrow was signifi cantly lower in the patient group than in the controls. 
No differences were found between patients and controls with respect to 
antigen-specifi c IgG or IgM. After subcutaneous immunization with KLH no 
differences were found between the two groups, neither in the antigen-specifi c 
IgA response, nor in IgG or IgM. This is the fi rst study in which persons are 
simultaneously immunized with two different neoantigens via two different 
routes. An IgA hyporesponse in IgAN patients after mucosal immunization 
was also observed after oral immunization with live typhoid vaccine [30]. 
It is important to realize that in both studies people were immunized with a 
neoantigen, so the described results represent a primary immune response. In 
general many immune responses after viral infections will be caused by recall 
antigens, leading to secondary immune responses, which are partly dependent 
on immunological memory. The contrast of mucosal IgA hyporesponse and 
higher IgA levels in the circulation could be explained by the hypothesis 
that decreased mucosal clearance of antigens can lead to prolonged immune 
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reactions leading to higher levels of immunological memory. No IgA hypo 
response was observed after the systemic immunization with KLH. Which 
factor or which factors are responsible for the observed IgA hypo response 
after mucosal immunization is not clear from this study. 
 Dentritic cells (DC) are professional antigen presenting cells and are 
involved in the initiation of immune responses. Besides DC can have a direct 
effect on B cells and are capable of skewing immunoglobulin production 
by naïve B cells towards IgA1 and IgA2 [33]. Therefore we postulated that 
DC could be responsible for the differences in IgA response between IgAN 
patients and controls. To test our hypothesis, nasal biopsies of IgAN patients 
and control persons were taken and stained for the presence of DC and subsets 
of DC. In chapter three we describe the result of this study showing that the 
number of DC in the nasal mucosa of IgAN patients is not decreased. As a 
matter of fact we even found higher numbers of CD1a positive DC in the 
epithelial layer and higher numbers of DC-SIGN positive cells in the lamina 
propria. 
 As the number of nasal mucosal DC in IgAN patients was not reduced 
as compared to controls, and therefore could not be responsible for the earlier 
described IgA hyporesponse, we postulated that the DC might be less effective 
in inducing IgA production by naïve B cells. In chapter four we investigated 
in an in vitro model the functional capacity of DC to induce IgA production 
in naïve B cells. The model used in this chapter is fi rst described by Fayette 
et al. [33]. In this model naive B cells are cultured in the presence of CD40L-
transfected cells, which mimic activated T cells. By making use of these 
transfected cells MHC restriction is bypassed. In these experiments we made 
use of monocyte-derived DC, CD40L-transfected cells and naïve B cells. 
The cells were cultured in the presence of different cytokines, like IL-10 and 
IL-2. The only variable in the system was the source of the DC, which was 
either from an IgAN patient or from a control person. In these experiments 
it appeared that DC derived from IgAN patients showed a reduced capacity 
to induce IgA production in the presence of IL-10. Although the mean IgA 
production induced by DC from IgAN patients was strongly reduced, DC 
from some individual patients induced a near normal IgA production. This 
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might refl ect that IgAN is a heterogeneous disease. No differences in IgG or 
IgM production where observed, independent of the different cytokines that 
were used. An experiment using supernatant of CD40 stimulated DC showed 
that the increase in immunoglobulin production induced by this supernatant 
was less than the induction by whole DC and that in this case no differences 
between patients and controls were present. This suggests that a membrane 
bound factor is responsible for the reduced functional capacity of DC from 
IgAN patients to induce IgA production by naïve B cells.
 From the results of chapter 2,3 and 4 it can be postulated that the IgA 
hyporesponse in IgAN patients observed after mucosal immunization can at 
least partially be explained by a functional defect of DC in the nasal mucosa, 
which is caused by a molecule present at the cell surface of DC. The number 
of sub-epithelial DC-SIGN positive DC and epithelial CD1a-positve DC in 
the nasal mucosa appeared to be increased in IgAN patients. This could be 
a compensatory increase for the described reduced capacity to induce IgA 
production.
IgA depositions in IgAN contain high levels of polymeric IgA. Therefore we 
were interested in the size distribution of antigen-specifi c IgA. In chapter 6 we 
describe that the antigen-specifi c IgA response contains high levels of polymeric 
IgA, both after mucosal and after systemic immunization. No differences in 
size distribution of antigen-specifi c IgA were present between IgAN patients 
and controls. Next to the size distribution of IgA we were interested in the 
presence of antigen-specifi c SIgA after mucosal immunization. A pathogenic 
role for SIgA is suggested by the fact that about 40% of IgAN patients have 
episodes of macroscopic hematuria, often preceded by upper respiratory tract 
infections [34]. Besides it was shown that SIgA is present in renal biopsies in 
15% of the cases. The presence of SIgA in renal biopsies correlates with the 
presence of MBL depositions. Although SIgA is mainly present at mucosal 
surfaces, in various secretions, low concentrations of SIgA are present in the 
circulation. In purifi ed IgA, the relative concentration of SIgA is higher in 
IgAN patients than in control persons [35]. In the study described in chapter 
6 we were able to detect small amounts of antigen-specifi c SIgA in the 
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circulation of both IgAN patients and controls, after mucosal immunization. 
This is to our knowledge the fi rst study showing antigen-specifi c SIgA in the 
circulation and supports the hypothesis that SIgA has a pathogenic role in a 
group of IgAN patients.
Disturbed 
mucosal IgA
immune response
Abnormal IgA1 
glycosylation
Increased IgA1 
production in bone 
marrow
Funtional defect(s) of 
dendritic cells
Production of cytokines 
and growth factors
??
Proliferation of mesangial cells
Glomerular sclerosis
Activation of complement 
system
IgA immune 
complexes
Increased plasma 
SIgA
Mesangial IgA1 
deposition
Figure 1. Overview of factors leading to mesangial IgA deposition and to progression 
of IgA nephropathy. A functional defect in DC might be responsible for the mucosal IgA 
hyporesponse and thereby to prolonged exposition to environmental antigens, eventually 
leading to higher levels of IgA memory cells and higher IgA plasma levels. Whether DC are 
directly involved in the glycosylation process of IgA and in the higher IgA production in the 
bonemarrow is speculative. The higher levels of SIgA in the circulation and the defective 
galactosylation of IgA will lead to mesangial deposition of IgA1. Once IgA is present in the 
kidney, this will lead to production of cytokines and growth factors and to activation of the 
complement system. Mesangial cells will proliferate, leading to glomerular sclerosis.
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As IgA derived from IgAN patients is abnormally O-glycosylated , we 
discussed this issue in chapter seven. Importantly, this undergalactosylated 
form of the IgA1 hinge region was also over-represented in biopsies of patients 
with IgAN [36]. Therefore, it is likely that this abnormally glycosylated IgA 
is involved in the pathogenesis of IgAN. This abnormal glycosylated IgA has 
a higher tendency to self-aggregate and form complexes with IgG antibodies 
directed against epitopes in the hinge region of IgA1. Besides, in patients 
with Henoch-Schönlein purpura, a disease closely related to IgAN with a 
similar renal histological pattern, only those patients who had abnormally 
glycosylated IgA had renal involvement, whereas patients with normally 
glycosylated IgA did not have renal involvement [37]. SIgA has a different 
glycosylation pattern as compared to other forms of IgA [38]. Whether SIgA 
of IgAN patients is aberrantly glycosylated is at present not known. 
IgAN is a heterogeneous disease, with a diverse and highly unpredictable 
outcome. The initial presentation can vary from microscopic hematuria with 
normal GFR, to gross macroscopic hematuria with end stage renal failure. 
Proteinuria can be absent, but can also be in the nephrotic range. Some 
patients remain stable for many years with a normal GFR, whereas others 
might develop end stage renal failure within a very short period of time. The 
histological hallmark of IgAN is the presence of IgA1 depositions in the renal 
mesangium, which is infl uenced by several factors (Figure 1). However, this 
picture can vary from slight mesangial hypertrophy with IgA1 depositions, 
to extracapillary proliferation with crescent formation. SIgA is present in 
renal biopsies in 15% of cases. Aberrant, undergalactosylated IgA1 seems 
to be involved in the pathogenesis. Since IgA1 glycosylation is determined 
within B lymphocytes, and only a fraction of the IgA1 seems to be affected, 
this suggests that alterations in glycosylation are only present in a subset of 
B cells. The question that arises is whether all these different clinical and 
histological pictures should be considered as one disease or that different 
characteristics represent a number of diseases with one common factor which 
is mesangial IgA deposition. 
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Further differentiation between IgAN patients, involving both immunological 
and histological investigations as well as clinical studies, is of importance to 
further unravel the pathogenesis of IgAN and eventually develop individual 
therapeutic strategies.
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Samenvatting
Het afweersysteem is er op gericht om bescherming te bieden tegen virussen 
en bacteriën, waaraan ieder mens dagelijks wordt bloot gesteld. Wanneer het 
lichaam hierdoor bedreigd wordt dan treedt een afweerreactie op, met als 
doel deze virussen en bacteriën onschadelijk te maken en te verwijderen. 
Tijdens deze afweerreactie worden cellen geactiveerd en worden uiteindelijk 
afweerstoffen (immuunglobulinen) geproduceerd, specifi ek gericht tegen 
eiwitten op het oppervlakte van deze bacteriën of virussen. Er zijn 5 
typen immuunglobulinen (Ig) namelijk, IgG, IgA, IgM, IgE en IgD. Deze 
afweerstoffen worden voornamelijk gemaakt door cellen in het bloed en 
in het beenmerg. IgA wordt echter ook in belangrijke mate gemaakt in de 
verschillende slijmvliezen (mucosa) van het lichaam, zoals in het slijmvlies 
van de luchtwegen en in het maag-darmstelsel. Soms is het immuunsysteem 
betrokken bij het ontstaan van een ziekte, zoals bij de ziekte IgA Nefropathie 
(IgAN).
 IgAN is de meest voorkomende primaire glomerulonefritis in de wereld. 
Een glomerulonefritis is een ontsteking van glomeruli, de fi lterlichaampjes 
van de nieren. Per nier zijn er ongeveer 1 miljoen glomeruli aanwezig. De 
ziekte IgAN kenmerkt zich door de aanwezigheid van IgA in het steunweefsel 
(mesangium). van de glomeruli. Het ontstaansmechanisme (pathogenese) van 
IgAN is onduidelijk. De reden waarom IgA neerslaat en de factoren die dit 
beïnvloeden zijn slechts ten dele bekend. Genetische factoren lijken een rol 
te spelen bij het ontstaan van IgAN. In bepaalde families, waar IgAN vaak 
voor komt, blijkt een gen mutatie aanwezig. Echter in het grootste aantal 
gevallen zijn tot op heden geen genetische factoren gevonden die het optreden 
van IgAN verklaren. Naast genetische factoren zijn waarschijnlijk ook 
omgevingsfactoren betrokken bij de pathogenese van IgAN. Dit kan deels 
verklaren waarom de incidentie van IgAN geografi sch sterke verschillen laat 
zien.
 De ziekte openbaart zich vaak tussen het 20e en 30e levensjaar en komt 
vaker voor bij mannen dan bij vrouwen in een verhouding 2:1. Kenmerken 
van IgAN zijn bloed in de urine (hematurie), vaak gepaard met eiwitverlies 
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via de urine (proteinurie) en tevens is er vaak sprake van hoge bloeddruk. Een 
opmerkelijk verschijnsel dat bij een aantal IgAN patiënten optreedt, is dat er 
zichtbaar bloed in de urine verschijnt, in aansluiting op een infectie, vaak van 
de bovenste luchtwegen. Het beloop van IgAN kan sterk variëren. Ongeveer 
30% van de patiënten zal uiteindelijk een totale nierinsuffi ciëntie ontwikkelen. 
Dit gebeurt meestal in de loop van vele jaren, maar kan ook in zeer korte tijd 
gebeuren. Om met zekerheid de diagnose IgAN te stellen is het noodzakelijk 
om een stukje nierweefsel onder de microscoop te beoordelen. Dit weefsel 
kan worden verkregen door middel van een prik in de nieren, een nierbiopsie, 
waarna met behulp van een specifi eke kleuringmethode het IgA kan worden 
gevisualiseerd. Vaak zijn er naast IgA ook nog andere eiwitten in de nier 
aanwezig, zoals IgG en C3, een ander eiwit betrokken bij de activatie van een 
deel van het immuunsysteem. De aanwezigheid van deze eiwitten leidt tot een 
ontstekingsreactie in de nier, waardoor er beschadiging optreedt en uiteindelijk 
verlies van nierfunctie. In Nederland en andere westerse landen is IgAN de 
oorzaak van nierfalen bij ongeveer 10% van de patiënten die nierfunctie 
vervangende therapie ondergaan. In het bloed van IgAN patiënten is IgA 
vaak in verhoogde concentratie aanwezig. Dit is echter nog geen verklaring 
voor het feit dat IgA in de glomeruli neerslaat. Bij andere aandoeningen, 
waarbij IgA soms ook in sterk verhoogde concentratie in het bloed aanwezig 
is, zoals bij HIV of bij de ziekte van Kahler, slaat IgA niet neer in de nieren. 
Opmerkelijk is dat na een niertransplantatie in de getransplanteerde nier vaak 
opnieuw neerslagen van IgA worden aangetroffen. Een enkele maal is het 
ook gebeurd dat een nier, die van een IgAN patiënt afkomstig bleek te zijn, 
werd getransplanteerd naar een niet IgAN patiënt. In een dergelijke situatie 
blijkt het IgA uit de nier te verdwijnen. Dit is een argument voor het feit dat 
IgAN wordt veroorzaakt door karakteristieken van het IgA en niet door een 
intrinsieke afwijking in de nieren. 
 IgA komt in het lichaam in verschillende vormen voor. Er bestaan twee 
subklassen, namelijk IgA1 en IgA2, die zich van elkaar onderscheiden door 
verschillen in het verbindingsstukje (hinge) tussen het constante en variable 
gedeelte, waardoor ook bepaalde suikergroepen op het molecuul verschillend 
aanwezig zijn. Alleen de subklasse IgA1 wordt in de nieren aangetroffen. 
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Verder wordt er een indeling van IgA gemaakt, gebaseerd op verschillen in 
grootte. Zo bestaat er monomeer IgA (mIgA), dat uit 1 IgA molecuul bestaat, 
dimeer IgA (dIgA) dat uit 2 IgA moleculen bestaat, verbonden door een 
eiwit genaamd J-chain, en polymeer IgA (pIgA), dat een variabele afmeting 
heeft en bestaat uit meerdere IgA moleculen. Met name pIgA wordt in de 
nieren van IgAN patiënten aangetroffen. Zoals eerder genoemd wordt IgA 
voornamelijk geproduceerd door cellen die aanwezig zijn in de slijmvliezen 
en wordt uitgescheiden in secreta, zoals speeksel en darmsappen. Dit IgA 
onderscheidt zich van IgA geproduceerd in het bloed of in het beenmerg, 
door de aanwezigheid van secretoir component en wordt secretoir IgA (SIgA) 
genoemd. Hoewel SIgA voornamelijk in secreta voorkomt en daar betrokken 
is bij het neutraliseren van virussen en bacteriën komt SIgA ook voor in de 
circulatie. De rol van SIgA in het bloed is niet duidelijk. Bij IgAN patiënten 
is de concentratie van SIgA in het bloed hoger dan bij gezonde personen. 
Bij een laag percentage IgAN patiënten wordt SIgA eveneens in de nieren 
aangetroffen en is geassocieerd met meer hematurie en de aanwezigheid van 
ontstekingseiwitten in de nier. 
 IgA van patiënten met IgAN verschilt niet alleen kwantitatief van IgA van 
gezonde personen, ook kwalitatief. Er zijn belangrijke verschillen aangetoond 
in de besuikering (glycosylering) van het IgA molecuul. Bovendien blijkt 
dit anders geglycosyleerde IgA in verhoogde mate aanwezig in de nieren. 
Welke factoren verantwoordelijk zijn voor de verandering in glycosylering is 
onduidelijk. 
Bij het op gang komen van een afweerreactie zijn verschillende cellen 
betrokken. In de eerste plaats zijn er cellen die een eiwit (antigeen) opnemen 
en dit in stukjes aan andere witte bloed cellen (T cellen) tonen, waardoor deze 
cellen geactiveerd kunnen raken. Deze antigeen presenterende cellen (APC) 
initiëren de immuunrespons. De belangrijkste APC is de dendritische cel 
(DC). Er zijn verschillende typen DC, die nog maar ten dele gekarakteriseerd 
zijn wat betreft hun functie. Een DC is ook in staat om een B cel (voorloper 
van een cel die immuunglobuline produceert) te laten veranderen in een 
plasmacel, een cel die een bepaald type Ig kan maken. Dit proces kan op 
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verschillende manieren plaatsvinden. Het kan door middel van activatie van 
bepaalde witte bloedcellen, T cellen, waarna deze T cel de B cel activeert en 
stimuleert tot Ig productie. Het kan echter ook door een direct effect van de 
DC op de B cel, waarbij de DC bepaalde signaaleiwitten afscheidt, die de B 
cel activeren, waarna proliferatie en differentiatie optreedt en er uiteindelijk 
een Ig producerende plasma cel ontstaat.
Het onderzoek, beschreven in dit proefschrift heeft zich gericht op verschillende 
aspecten van regulatie van de immuunrespons van IgAN patiënten. Hoofdstuk 
2 gaat over een vaccinatie studie, waarbij IgAN patiënten en gezonde controle 
personen worden gevaccineerd met twee verschillende eiwitten, waarmee 
deze personen nog niet eerder in contact zijn geweest (neo-antigenen). Een 
dergelijke toediening leidt tot een zogenaamde primaire immuun respons. 
Het ene antigeen, Cholera Toxine B subunit (CTB) wordt toegediend op de 
slijmvliezen van de neus. Het andere eiwit, Keyhole Limpet Hemocyanin 
(KLH) wordt onder de huid toegediend. In totaal krijgen alle personen 3 maal 
deze eiwitten toegediend. Het blijkt dat de IgAN patiënten na de mucosale 
vaccinatie met CTB minder IgA gericht tegen het CTB maken dan de gezonde 
personen. Er wordt geen verschil gevonden tussen de beide groepen in de IgG 
en de IgM antistoffen gericht tegen CTB. Na de vaccinatie met KLH worden 
geen verschillen in concentratie van afweerstoffen gevonden tussen de beide 
groepen. 
 Aangezien het een primaire immuunrespons betreft, waarbij de DC een 
belangrijke rol speelt, hebben we gepostuleerd dat er minder DC aanwezig 
zijn bij IgAN patienten. Vervolgens hebben we gekeken naar de aanwezigheid 
van DC in de mucosa van de neus, de plaats waar het vaccin werd toegediend. 
Dit wordt beschreven in hoofdstuk 3. Het blijkt dat IgAN patiënten niet 
minder DC in de neus mucosa hebben dan de controle personen. Van bepaalde 
subtypen zijn er zelfs meer DC bij de IgAN patiënten aanwezig. Dit betekent 
dat de eerder gevonden IgA hyporespons niet verklaard kan worden door een 
tekort aan DC bij IgAN patiënten. 
Om te onderzoeken of de aanwezige DC minder goed functioneren, hebben 
we gebruik gemaakt van een in vitro model. Dit model en de resultaten 
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van het onderzoek worden beschreven in hoofdstuk 4. In dit model wordt 
een primaire immuunrespons nagebootst. Daarbij wordt gebruik gemaakt 
van B cellen die nog niet eerder bij een immuun respons betrokken zijn 
geweest, zogenaamde naïeve B cellen, en van cellen die de geactiveerde T 
cel nabootsten. Aan deze cellen worden DC toegevoegd die zijn opgekweekt 
uit monocyten, voorlopercellen van DC, geïsoleerd uit het bloed van IgAN 
patiënten en van gezonde vrijwilligers. De enige variabele in dit model is de 
DC. Het blijkt dat onder deze gecontroleerde omstandigheden naïeve B cellen 
kunnen worden gestimuleerd om zich te ontwikkelen tot Ig producerende 
plasmacellen. Afhankelijk van de omstandigheden wordt er meer IgA, IgG 
of IgM geproduceerd. De aanwezigheid van DC verhoogt de productie van 
Ig in hoge mate. DC afkomstig van IgAN patiënten induceerden minder IgA 
productie dan DC afkomstig van controle personen. Er was geen verschil in de 
productie van IgG en IgM. Hoewel er onderling variatie was in het vermogen 
B cellen aan te zetten tot IgA productie tussen de verschillende IgAN patiënten 
was de gemiddelde IgA productie veel lager dan bij de controle personen. 
 De resultaten van de hoofdstukken 2,3 en 4 tonen dat DC van patiënten 
met IgAN funtioneel tekort schieten in het induceren van een primaire IgA 
immuunrespons. Onze hypothese is dat door het minder effectieve verloop 
van deze primaire mucosale IgA immuunrespons de totale expositieduur aan 
mucosale antigenen verlengd wordt, met als gevolg uiteindelijk een hogere 
concentratie afwijkend IgA in het bloed, wat kan bijdragen aan het neerslaan 
van IgA in de nieren. 
  Zoals eerder vermeld, wordt een belangrijk deel van de totale 
hoeveelheid IgA in de mucosa geproduceerd en dit wordt als secretoir IgA 
(SIgA) uitgescheiden in de diverse secreta. Bij de meeste IgAN patiënten is 
de concentratie van SIgA in het bloed verhoogd en bij 15% van de patiënten 
wordt in de nieren ook SIgA aangetroffen. In de hoofdstukken 5 en 6 wordt 
dieper ingegaan op de rol van SIgA. Hoofdstuk 5 is een overzichtsartikel, 
dat een algemene beschrijving geeft van de verschillende aspecten van SIgA 
en de rol van SIgA beschrijft in relatie tot IgAN. In hoofdstuk 6 tonen we 
aan dat er antigeen-specifi ek SIgA kan worden aangetoond in het bloed van 
personen die mucosaal gevaccineerd zijn. Hierbij hebben we gebruik gemaakt 
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Samenvatting
van de bloedmonsters van de personen uit de vaccinatie studie van hoofdstuk 
2. Tevens hebben we gekeken hoe de verdeling in grootte is van de specifi eke 
IgA respons na de mucosale en subcutane vaccinatie. Het is immers zo dat met 
name pIgA in de nieren neerslaat. Het blijkt dat zowel IgAN patienten als ook 
gezonde personen tijdens een primaire immuun respons voornamelijk pIgA 
produceren. Dit geldt voor de beide vormen van immunisatie. Deze studie 
is de eerste studie die het mogelijk maakt om de grootteverdeling van IgA 
moleculen na verschillende vormen van immunisatie met elkaar te vergelijken. 
Tussen beide groepen kunnen geen verschillen in grootteverdeling van het 
antigeen specifi eke IgA worden aangetoond. Aangezien slechts een klein 
deel van het IgA uit het bloed neerslaat in de nieren is het goed mogelijk dat 
aanwezige subtiele verschillen in grootteverdeling van het IgA, niet gevonden 
zijn doordat de gebruikte methodes tekort schieten.
 Hoofdstuk 7 beschrijft een ander belangrijk aspect van IgAN, namelijk 
de glycosylering (besuikering) van het IgA molecuul. In vele studies is 
inmiddels aangetoond dat de glycosylering een belangrijke rol speelt bij het 
ontstaan van IgAN. Patiënten met IgAN hebben IgA dat anders geglycosyleerd 
is in vergelijking met controle personen. Dit IgA heeft een verhoogde neiging 
tot complex vorming. Bovendien bevatten de neerslagen van IgA met name 
dit afwijkend geglycosyleerde IgA. Recent is er onderzoek gedaan naar 
enzymen die betrokken zijn bij dit glycosylerings proces. Het blijkt dat de 
aanwezigheid van deze enzymen en ook de gen expressie van deze enzymen 
niet verschillend is tussen patiënten en controles. Het is belangrijk te beseffen 
dat slechts een deel van het IgA van IgAN patiënten afwijkend geglycosyleerd 
is. Welke factoren bepalen hoe de glycosylering verloopt en welke factoren 
verantwoordelijk zijn voor het feit dat een deel van het IgA afwijkend 
geglycosyleerd is blijft nog onduidelijk.
 Het bovenstaande toont aan dat bij IgAN patiënten gezocht moet worden 
naar afwijkingen in het immuunsysteem. Het onderzoek, zoals beschreven in 
dit proefschrift heeft zich gericht op de immuunrespons bij patiënten met IgAN, 
omdat met name de afwijkingen in de immuun respons van invloed kunnen 
zijn op het ontstaan van een verhoogde concentratie van afwijkend IgA in het 
bloed en daarmee van invloed kunnen zijn op het ontstaan van IgAN. Daar 
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het immuunsysteem een uitermate complex systeem is, waarbij vele eiwitten 
betrokken zijn en waarbij nog steeds nieuwe eiwitten en signaleringsroutes 
ontdekt worden, moge duidelijk zijn dat het oplossen van de pathogenese van 
IgAN een moeilijke zaak is, die verdergaand onderzoek noodzakelijk maakt 

 163
Curriculum Vitae
De schrijver van dit proefschrift werd geboren op 13 februari 1966 te 
Pijnacker. In 1984 behaalde hij het VWO ß diploma aan het Christelijk 
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Het tot stand komen van dit proefschrift is het resultaat van een proces 
waaraan vele personen hebben bijgedragen. Graag wil ik dan ook iedereen 
die op welke manier dan ook betrokken is geweest bij het onderzoek hiervoor 
bedanken. 
In het bijzonder wil ik noemen:
De patiënten met IgA nefropathie die telkens weer bereid waren om mee 
te werken aan dit onderzoek. Velen hebben gedurende enkele jaren met 
regelmaat hun medewerking verleend en toonden zich hierin fl exibel. Zonder 
hun bijdrage zou het onmogelijk zijn dit type onderzoek te verrichten. 
Alle medewerkers van het laboratorium Nierziekten, waarmee ik met 
veel plezier gedurende langere tijd gewerkt heb. Altijd weer bleken jullie 
hulpvaardig en dachten mee in het oplossen van problemen op velerlei gebied. 
Op deze manier zorgden jullie er met elkaar voor dat het mogelijk was voor 
mij om als arts, basaal onderzoek te doen. Ik heb me altijd thuis gevoeld op 
het laboratorium en daar ben ik jullie dankbaar voor. Ook bedank ik jullie 
voor het mij in contact brengen met vernieuwende muziek soorten en het op 
de hoogte houden van nieuwe trends, die soms verassend genoeg mij geheel 
onopgemerkt waren gebleven.
Sylvia Kamerling, steun en toeverlaat. Sylvia, met veel plezier denk ik terug 
aan de tijd dat ik met jou mocht werken. De dagen op het laboratorium waren 
gezellig en berucht, wanneer we samen als “Jut en Jul” weer eens een (te) 
groot opgezet experiment hadden georganiseerd. Dankzij jouw arbeid en 
kunde is een en ander tot een goed einde gekomen. Ik zal de samenwerking 
missen!
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Alle co-auteurs voor hun actieve bijdragen aan de diverse hoofdstukken. 
De mensen van de KNO afdeling van het Academisch Medisch Centrum 
te Amsterdam, Susanne Reinartz en Kees van Drunen, voor de goede 
samenwerking en het inbrengen van hun kennis.
De stafl eden van de afdeling Nierziekten en mijn collega fellows van de afdeling 
Nierziekten, voor de leuke en leerzame tijd die ik heb mogen doormaken. Met 
name mijn beide kamergenoten Marc Seelen en Eduard Scholten, voor de 
goede tijd die we hebben gehad, voor de opbeurende woorden na mislukte 
experimenten, maar bovenal voor de vriendschap, gegroeid in de Tora Bora 
tijd. Ik ben blij dat jullie beide paranimf willen zijn.
De secretaresses van het secretariaat Nierziekten, voor alle hulp gedurende 
het gehele promotie traject.
Wijlen Prof. Dr. L.C. Paul, voor de kritische input tijdens het begin van het 
onderzoek en de daaruit voortvloeiende adviezen, die niet zelden doorspekt 
waren met de nodige humor. 
Mijn maatschapsleden van de maatschap Interne Geneeskunde en Maag-Darm-
Leverziekten in Gouda, voor hun morele support tijdens het onderzoek. Jullie 
hebben van het begin af aan mij de keuze gelaten en de mogelijkheid geboden 
om dit onderzoek en de klinische taken te combineren, dank hiervoor.
De overige medewerkers van het Groene Hart Ziekenhuis in Gouda, die 
dagelijks bijdragen aan de goede werksfeer.
Mijn schoonouders, Mieke en Arie. Niet alleen toonden jullie veel interesse in 
het onderzoek maar boden tevens fl exibele inzet bij tal van zaken. Dank voor 
het oppassen op onze drie goudklompjes.
Mijn ouders. Mama, dank voor de onbezorgde jeugd en voor alles wat toen zo 
gewoon en vanzelfsprekend leek. Dank voor alle mogelijkheden die jullie mij 
geboden hebben. Ouders te hebben als jullie is bijzonder. Het is moeilijk dat 
papa er niet meer is, hij zou er vandaag zeker van genoten hebben.
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Bram, Coen en Emile, jongens jullie hebben wat geduld nodig gehad, maar 
het “proefwerk” is eindelijk klaar. Ik hou van jullie zoals jullie zijn en ben blij 
dat we samen ondanks de drukte veel tijd hebben doorgebracht. Als ik jullie 
zie en hoor besef ik wat geluk is en wat ik bof dat jullie mijn kinderen zijn. 
Tot slot Iris. You are the wind beneath my wings. 
Dank voor alles, maar vooral voor wie je bent.

